

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 1 238 100 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:

07.09.2005 Bulletin 2005/36

(21) Application number: 00948890.9

(22) Date of filing: 21.07.2000

(51) Int Cl.7: C12Q 1/68, C12Q 1/70

(86) International application number:  
PCT/US2000/020034

(87) International publication number:  
WO 2001/007661 (01.02.2001 Gazette 2001/05)

### (54) POLYNUCLEOTIDE AMPLIFICATION METHOD

POLYNUKLEOTID AMPLIFIZIERUNGSVERFAHREN

METHODE D'AMPLIFICATION DE POLYNUCLEOTIDES

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

(30) Priority: 23.07.1999 US 145432 P

(43) Date of publication of application:  
11.09.2002 Bulletin 2002/37

(73) Proprietor: GEN-PROBE INCORPORATED  
San Diego, CA 92121-4362 (US)

(72) Inventor: NUNOMURA, Kiyotada  
Tokyo 188-0013 (JP)

(74) Representative: Viering, Jentschura & Partner  
Postfach 22 14 43  
80504 München (DE)

(56) References cited:

EP-A- 0 731 174 WO-A-95/02067  
WO-A-98/58086 US-A- 5 710 029

- GEMEN VAN B ET AL: "THE ONE-TUBE QUANTITATIVE HIV-1 RNA NASBA: PRECISION, ACCURACY, AND APPLICATION" PCR METHODS & APPLICATIONS, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 4, no. 4, 1 February 1995 (1995-02-01), pages S177-S184, XP000579764 ISSN: 1054-9803
- DATABASE EMBL [Online] ID:HIVBH102, 7 May 1992 (1992-05-07) WONG-STAAL ET AL.: "HIV-1, isolate BH10, genome" XP002183254
- KELLOGG DE ET AL.: "Quantitation of HIV-1 Proviral DNA Relative to Cellular DNA by the Polymerase Chain Reaction" ANALYTICAL BIOCHEMISTRY, vol. 189, 1990, pages 202-208, XP000386282
- PIATAK M ET AL.: "Quantitative Competitive Polymerase Chain Reaction for Accurate Quantitation of HIV DNA and RNA Species" BIOTECHNIQUES, vol. 14, no. 1, 1993, pages 70-81, XP000331780
- ERLICH HA: "PCR TEchnology" 1989 , STOCKTON PRESS , NEW YORK XP002183252 Chapter 1: "The Design and Optimization of the PCR" (R. Saiki) page 14 -page 15
- INNIS MA ET AL.: "PCR Protocols - A Guide to Method and Applications" 1989 , ACADEMIC PRESS , SAN DIEGO, US XP002183253 page 10

EP 1 238 100 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**Field of the Invention

5 [0001] The present invention relates to methods and compositions useful for improving the precision and quantitative capacity of polynucleotide amplification reactions commonly performed in molecular genetics laboratories.

Background of the Invention

10 [0002] Enzyme-based procedures for amplifying polynucleotides are now established tools for diagnostic, environmental and forensic testing. The market for DNA probe diagnostics in clinical laboratories now represents several hundred million dollars each year. The clinical diagnostics-probe business is expected to grow with viral screening and viral load determination representing major areas of active market expansion. Given the commercial value of this technology, great efforts have been invested in research and development of improved amplification procedures (see

15 *Genetic Engineering News* 17:6 (1997)).

[0003] Recently developed techniques for amplifying analyte polynucleotides have provided useful alternatives to methods based on the original Polymerase Chain Reaction (PCR) protocol. According to one technique, DNA amplification reactions are performed on solid-phase substrates made alternatively of glass, plastic, a semiconductor chip or a fiber-optic array. Labeled target DNA is synthesized as a molecular bridge between pairs of oligonucleotide primers 20 immobilized to the solid substrate such that the amplification products remain attached to the solid substrate. U.S. Patent No. 5,399,491 discloses a different technique wherein a target polynucleotide is amplified autocatalytically under conditions of substantially constant temperature, ionic strength and pH. This method, termed Transcription Mediated Amplification (TMA), allows for the synthesis of multiple RNA copies of target sequence. New methods likely to emerge 25 in the future will continue to expand the range of applications that can be addressed by polynucleotide amplification techniques.

[0004] Quantitative amplification assays represent one subset of assays that impose stringent requirements on all aspects of the procedure, including template isolation and standardizing amplification efficiency. Approaches that employ internal standards that participate in amplification reactions are intended to normalize reaction efficiency, but fail 30 to account for variable levels of analyte polynucleotide input into the reaction. Related methods that simultaneously amplify an analyte polynucleotide and control polynucleotides derived from constitutively expressed housekeeping genes also are imperfect because multiple primer sets are required to carry out the amplification reaction.

[0005] One example of methods based on the use of internal standards in quantitative PCR amplifications is disclosed 35 in U.S. Patent No. 5,219,727. According to the method disclosed in this patent, the internal standard is included in the amplification reaction and is designed so that it will amplify at a similar efficiency as the target polynucleotide. Like methods that co-amplify constitutively expressed gene products for use as internal standards, the method disclosed in U.S. Patent No. 5,219,727 requires detecting and quantifying the amplicon derived from the internal standard in order to quantify the analyte polynucleotide. Thus, several steps still are required to quantitate analyte polynucleotides when an internal standard must be detected and quantitated.

[0006] Another example is the method disclosed in WO-A-9502067 (Akzo Nobel, 1995), that allows quantitation of 40 an analyte polynucleotide by relating the pre-determined amount of a pseudo target to the amount of said analyte polynucleotide.

[0007] A further example is the method exemplified in US-A-5710029 (Ryder et al., 1998), allowing the reduction of a non-specific background in a nucleic acid amplification reaction by co-amplifying a pre-determined amount of a pseudo target and the analyzing and quantifying the analyte polynucleotide in a sample by relating both amounts.

[0008] The fact that amplified polynucleotides ("amplicons") in conventional PCR and TMA procedures are synthesized as molecules free in solution represents another source of inaccuracy for analyte detection. These amplicons can easily be transferred between samples to produce false-positive results in the contaminated reactions. Standard precautions for minimizing false-positive results due to contamination by carried-over DNA templates include ultraviolet 45 irradiation of pipetting devices, the use of disposable glass- and plastic-ware, use of separate laboratories or laboratory areas for conducting amplification reactions, and avoiding the formation of aerosols. One elaborate approach for ensuring that PCR products cannot be re-amplified in subsequent reactions involves a series of steps using specialized reagents to degrade the products from previous PCR amplifications. However, this procedure is somewhat complicated and involves first substituting dUTP for dTTP in the PCR mixture and then pretreating all subsequent PCR mixtures with a uracil N-glycosylase (UNG) enzyme prior to PCR amplification. Products from previous PCR amplifications are 50 then eliminated by excising uracil residues using UNG, and degrading the resulting abasic polynucleotide (Longo, et al., *Gene* 93:125 (1990)). Clearly, these methods do not lend themselves to high throughput assays.

[0009] Accordingly, there exists a continuing need for techniques that can be used to enhance the precision of polynucleotide amplification procedures. Further, there exists a need for techniques that can be used to diminish the inci-

dence of false-positive results arising from positive carry-over contamination. The present invention addresses both of these needs.

### Summary of the Invention

**[0010]** A first aspect of the invention relates to a method for quantifying analyte polynucleotides that are present in a test sample. The method includes steps for: (1) combining a predetermined amount of a test sample, containing an unknown amount of an analyte polynucleotide, with a predetermined amount of a pseudo target; (2) co-amplifying in a polynucleotide amplification reaction the analyte polynucleotide and the pseudo target to produce a collection of amplification products that includes both an analyte amplicon if the sample contained the analyte polynucleotide and a pseudo target amplicon; and (3) quantifying the analyte amplicon without relying on information regarding the amount of pseudo target amplicon produced in the reaction, whereby the quantity of analyte amplicon is related in a dose-dependent manner to the unknown amount analyte polynucleotide that was present in the original test sample. Optionally there can be an added step for detecting the pseudo target amplicon. This optional step may be useful, for example, as a positive control for the amplification reaction. In certain preferred embodiments of the invention, the step for quantifying the analyte amplicon involves first hybridizing the collection of amplification products from the co-amplifying step with a labeled probe that is specific for the analyte amplicon but not the pseudo target amplicon, and then detecting any labeled probe that specifically hybridized to the analyte amplicon. Of course, it is to be understood that the analyte amplicon-specific probe can be a probe that binds the analyte polynucleotide or a nucleic acid strand that is complementary thereto. In other embodiments, the polynucleotide amplification reaction in the co-amplifying step can be any one of a Transcription Mediated Amplification (TMA) reaction, a NASBA reaction or a Polymerase Chain Reaction, with the TMA reaction representing a highly preferred embodiment of the invention. Regardless of the type of amplification reaction that is employed, the obtaining step can involve first collecting a biological specimen and then releasing nucleic acids contained in the specimen to result in the sample that contains the unknown amount of analyte polynucleotide. For all types of amplification reactions the amount of pseudo target in the combining step preferably is between  $1 \times 10^3$  and  $2 \times 10^8$  molecules, more preferably between  $1 \times 10^4$  and  $2 \times 10^8$  molecules, and still more preferably between  $1 \times 10^5$  and  $2 \times 10^8$  molecules. Optionally there can be included an additional step for capturing the analyte polynucleotide onto a solid support prior to the co-amplifying step. In embodiments of the invented method that employ the additional capturing step the amount of pseudo target used in the combining step preferably ranges from between  $1 \times 10^3$  and  $2 \times 10^8$  molecules, more preferably between  $1 \times 10^4$  and  $2 \times 10^8$  molecules, and still more preferably between  $1 \times 10^5$  and  $2 \times 10^8$  molecules. An exemplary solid support is a bead that is derivatized with a synthetic polynucleotide. The biological specimen used in the procedure can be a blood sample or a plasma sample, and the nucleic acids contained in the specimen can include viral nucleic acids. In one embodiment of the invention, the analyte polynucleotide used in the procedure is a nucleic acid that is released from HIV virions. When the polynucleotide amplification reaction used in the invented method is the TMA reaction, there can be included in the method a further step for isolating the analyte polynucleotide and the pseudo target after the combining step and before the co-amplifying step. In embodiments of the invented method wherein the Transcription Mediated Amplification reaction is employed, the amount of the pseudo target used in the reaction preferably is between  $1 \times 10^3$  and  $2 \times 10^8$  molecules, more preferably between  $1 \times 10^4$  and  $2 \times 10^8$  molecules, and still more preferably between  $1 \times 10^5$  and  $2 \times 10^8$  molecules. When the step for quantitatively detecting involves hybridizing a labeled probe that is specific for the analyte amplicon, the labeled probe can be labeled with acridinium ester, in which case the step for quantitatively detecting may involve performing luminometry. In embodiments of the invention wherein first step involves releasing nucleic acids contained in a biological specimen, the analyte polynucleotide can be a viral polynucleotide. In general, the invented method can involve the further step of consulting a standard curve that relates pre-amplification amounts of analyte polynucleotide and post-amplification amounts of analyte amplicon. This step for consulting a standard curve also is applicable when luminometry is employed to measure hybridization of probes labeled with acridinium ester, or when the amplification reaction is particularly a Transcription Mediated Amplification reaction. In still other preferred embodiments that employ the Transcription Mediated Amplification reaction, a paired set of oligonucleotide primers having the sequences of SEQ ID NO:1 and SEQ ID NO:2 can be used for conducting the reaction, and the pseudo target can have a polynucleotide sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:9.

**[0011]** Another aspect of the invention concerns a method for relating pre-amplification amounts of analyte polynucleotide and post-amplification amounts of analyte amplicon. This method includes steps for: (1) obtaining a plurality of control samples that include different predetermined amounts of an analyte polynucleotide; (2) combining each of the plurality of samples with a constant amount of a pseudo target to result in a plurality of mixed samples; (3) co-amplifying in a plurality of amplification reactions both the pseudo target and any of the analyte polynucleotide present in each of the plurality of mixed samples to produce amplification products, the amplification products including both a pseudo target amplicon for each of the plurality of mixed samples and an analyte amplicon for any of the plurality of mixed samples that contained the analyte polynucleotide; (4) quantifying the analyte amplicon for each of the plurality

of amplification reactions without reference to the amount of pseudo target amplicon present in the collection of amplification products; and (5) preparing a standard curve having the different predetermined amounts of analyte polynucleotide plotted against the quantified amounts of analyte amplicon for each of the plurality of amplification reactions, thereby relating the pre-amplification amounts of analyte polynucleotide present in each of the plurality of control samples and the post-amplification amounts of analyte amplicon synthesized in each of the amplification reactions. Optionally there can be an added step for detecting the pseudo target amplicon. This optional step may be useful, for example, as a positive control for the amplification reaction. In a preferred embodiment the analyte polynucleotide is a viral polynucleotide, such as an HIV polynucleotide. Generally, the constant predetermined amount of pseudo target can range between  $1 \times 10^3$  and  $2 \times 10^8$  molecules, more preferably between  $1 \times 10^4$  and  $2 \times 10^8$  molecules, and still more preferably between  $1 \times 10^5$  and  $2 \times 10^8$  molecules. According to other embodiments of the invented method, the plurality of amplification reactions in the co-amplifying step can be any of a plurality of Transcription Mediated Amplification reactions, a plurality of NASBA reactions and a plurality of PCR reactions. In a collection of highly preferred embodiments, the amplification reactions in the co-amplifying step are Transcription Mediated Amplification reactions. Regardless of the type of amplification reactions that are employed, the quantifying step can involve first hybridizing the amplification products from the co-amplifying step with a labeled probe specific for the analyte amplicon but not the pseudo target amplicon and then quantitatively detecting any labeled probe that specifically hybridized. In certain instances, the labeled probe is labeled with acridinium ester. In still other preferred embodiments wherein the quantifying step involves hybridization with a labeled analyte amplicon-specific probe, there can be an additional step for capturing the analyte polynucleotide onto a solid support prior to the co-amplifying step.

**[0012]** Also disclosed are kits that can be used for performing polynucleotide amplification reactions according to the described method using analyte polynucleotide templates. Exemplary kits can include: a pseudo target; at least one pair of oligonucleotide primers for co-amplifying the pseudo target and the analyte polynucleotide; reagents for carrying out the polynucleotide amplification reaction, including deoxynucleotide triphosphates and a DNA polymerizing enzyme; and printed instructions with directions for first carrying out the amplification reaction and then detecting only analyte amplicons produced in the amplification reaction. In one embodiment, the invented kit can also include a labeled probe for detecting any analyte amplicons produced in the amplification reaction. According to another embodiment, the invented kit further includes nucleotide triphosphates and an RNA polymerizing enzyme. The DNA polymerizing enzyme included in the kits can be a reverse transcriptase. In a highly preferred embodiment, no RNase H additional to that provided by the reverse transcriptase is used in the kit.

**[0013]** Yet another aspect of the invention relates to a qualitative method of determining whether a biological sample contains an analyte polynucleotide. This method includes steps for: (1) combining a biological sample with a pseudo target to result in a mixed sample; (2) isolating nucleic acids from the mixed sample, whereby there is obtained a collection of molecules that include the pseudo target and any of the analyte polynucleotide present in the biological sample; (3) conducting a polynucleotide amplification reaction to co-amplify the pseudo target and any of the analyte polynucleotide contained in the collection of molecules to produce amplification products, whereby pseudo target amplicons are formed, and whereby analyte amplicons are formed if the collection of molecules included the analyte polynucleotide; (4) detecting in the amplification products any of the analyte amplicons without detecting the pseudo target amplicons; and (5) determining that the biological sample contains the analyte polynucleotide if the analyte amplicons are detected among the amplification products. In certain embodiments, the amplification reaction is any of a Transcription Mediated Amplification reaction, a NASBA reaction and a PCR reaction. In certain highly preferred embodiments, the amplification reaction is a Transcription Mediated Amplification reaction. Regardless of the type of amplification reaction that is employed, the detecting step can involve first hybridizing a labeled polynucleotide probe having binding specificity for the analyte amplicons and then measuring the extent of specific binding of the labeled polynucleotide probe. When the detecting step involves hybridizing a labeled analyte amplicon-specific probe, the isolating step can involve immobilizing the pseudo target and the analyte polynucleotide to a solid support. According to another preferred embodiment, the detecting step involves detecting by luminometry. In still yet another preferred embodiment, the analyte polynucleotide is from HIV virions. When this is the case, the pseudo target can have a sequence that is either SEQ ID NO:4 or SEQ ID NO:9.

## 50 Definitions

**[0014]** As used herein, the following terms have the following meanings unless expressly stated to the contrary.

**[0015]** A "polynucleotide" may be either RNA or DNA unless specified otherwise.

**[0016]** An "oligonucleotide" is a polynucleotide molecule having a length of from 10 to 100 nucleotides, or more preferably 10 to 50 nucleotides. Ordinarily, oligonucleotides will be synthesized by organic chemical methods and will be single-stranded unless specified otherwise. Oligonucleotides may be labeled with a detectable label.

**[0017]** An "amplicon" is a polynucleotide product generated in an amplification reaction.

**[0018]** An "analyte amplicon" is a polynucleotide product of an amplification reaction wherein an analyte polynucle-

otide served as the template for synthesis of polynucleotide copies or amplification products.

[0019] An "analyte polynucleotide" is a target polynucleotide that is to be replicated by a nucleic acid amplification process such as the TMA protocol, but is structurally distinguishable from a pseudo target polynucleotide. The two polynucleotides may be distinguishable, for example, by virtue of the presence or absence of a restriction enzyme cleavage site or an internal sequence difference that is distinguishable by a hybridization probe.

[0020] A "target polynucleotide" has a target sequence to be replicated, may be either single-stranded or double-stranded, and may include sequences in addition to the target sequence, which additional sequences may not be amplified.

[0021] A "target sequence" refers to the particular nucleotide sequence of the target polynucleotide which is to be amplified. The target sequence includes the complexing sequences to which oligonucleotide primers useful in the amplification reaction can hybridize prior to extension by a DNA polymerase. Where the target polynucleotide is originally single stranded, the term "target sequence" will also refer to the sequence complementary to the target polynucleotide. Where the target polynucleotide is originally double-stranded, the term "target sequence" refers to both the (+) and (-) strands that are complementary to each other.

[0022] A "pseudo target" is a polynucleotide that can be co-amplified with the analyte polynucleotide in a single amplification reaction. The pseudo target and the analyte polynucleotide is amplified using the same set of oligonucleotide primers. The pseudo target and the analyte polynucleotide will be nonidentical molecules so that the analyte polynucleotide and the pseudo target can be distinguished from each other.

[0023] A "pseudo target amplicon" is a polynucleotide product of an amplification reaction wherein a pseudo target served as the template for synthesis of polynucleotide copies or amplification products.

[0024] A "polynucleotide amplification reaction" is a template-dependent *in vitro* enzyme-catalyzed reaction for increasing the number of target polynucleotides.

[0025] In the context of the invention, "quantitatively detecting" or "quantifying" refers to a process for determining the extent of polynucleotide or amplicon production.

[0026] A "labeled probe" is a nucleotide polymer that harbors a detectable moiety and that can combine with a complementary single-stranded target nucleic acid sequence to form a double-stranded hybrid. The term also includes analogs of naturally occurring nucleotides and particularly includes analogs having a methoxy group at the 2' position of the ribose (OMe). The detectable moiety may be attached to the end(s) of the probe or may be positioned internally within the sequence of the probe. In general, labeled probes will be about 10 to about 100 nucleotides in length, but can be longer than 100 or shorter than 10 nucleotides,

[0027] A "detectable moiety" is a molecule attached to, or synthesized as part of, a labeled probe. This molecule should be uniquely detectable and will allow the probe to be detected as a result. These detectable moieties are often radioisotopes, chemiluminescent molecules, enzymes, haptens, or even unique oligonucleotide sequences.

[0028] A "labeled probe specific for an analyte amplicon" is a labeled probe having a polynucleotide sequence complementary to a polynucleotide product synthesized in an amplification reaction wherein an analyte polynucleotide served as the template for synthesis of amplification products. Since an amplicon is a polynucleotide product generated in an amplification reaction, the labeled probe specific for the analyte amplicon can be complementary to any polynucleotide strand generated in the reaction. Thus, if an analyte polynucleotide is a single-stranded molecule that contains a target sequence, and if copies of the target sequence and its complement are generated in the amplification reaction, then the labeled probe specific for the analyte amplicon can be complementary to the target sequence or its complement.

[0029] "Co-amplifying" as used herein refers to the process of amplifying in a polynucleotide amplification reaction more than one species of target polynucleotide. For example, "co-amplifying an analyte polynucleotide and a pseudo target" is intended to refer to the process of simultaneously amplifying the two polynucleotides to result in the formation of analyte amplicons and pseudo target amplicons, respectively.

[0030] As used herein "obtaining" a sample that includes, or that may include, an analyte polynucleotide can mean either obtaining from a biological subject such as a human, or obtaining from a reagent depository, such as a commercial vendor. When a sample is obtained from an animal or a human it will be understood that any number of appropriate means familiar to those having ordinary skill in the art can be employed. For example, if a blood sample is obtained, it can be obtained either by drawing blood through venepuncture, but also can be obtained as a forensic sample.

[0031] As used herein, the phrase "without reference to the amount of pseudo target amplicon" means that quantitative information regarding the amount of pseudo target amplicon synthesized in an amplification reaction is not required to make a determination regarding another parameter in an amplification system. For example, the synthesized amount of analyte amplicon in an amplification system or the amount of analyte polynucleotide that would have led to the formation of that amount of amplicon can be determined according to the methods disclosed herein without quantitative information about the formation of pseudo target amplicons in the same reaction. Indeed, it is not even necessary to detect the pseudo target amplicon for success of the quantitative method described herein. The present invention provides an approach for relating the pre-amplification amount of analyte polynucleotide and the post-amplification

amount of analyte amplicon. This relationship can be established without relying on, or even having knowledge about, the amount of pseudo target amplicon that is co-amplified with the analyte amplicon in an amplification reaction. Thus, even if the pseudo target amplicon is detected or quantified in an experimental procedure, it is unnecessary to employ that information when relating the pre-amplification amount of an analyte polynucleotide and the post-amplification amount of a corresponding analyte amplicon.

[0032] As used herein, a "standard curve" is a representation that relates a pre-amplification amount of a polynucleotide and a post-amplification amount of a corresponding amplicon. For example, a standard curve can be a graph having known numbers of input template molecules on the x-axis, and either RLU values or pmols of amplicon product plotted on the y-axis. Standard curves typically are produced using control polynucleotide standards having known numbers or polynucleotide templates. Standard curves can be stored in electronic form or can be represented graphically.

[0033] A "biological specimen" is a sample of material derived from an organism.

#### Brief Description of the Drawings

##### [0034]

Figure 1 is a schematic representation of electrophoretically separated TMA reaction products synthesized using different amounts of input target polynucleotide template. The lane marked "Neg" represents a reaction that did not include input template. The remaining lanes represent reactions conducted using increasing amounts of input target polynucleotide. The position on the gel of the specific amplification product derived from the target polynucleotide is marked by an arrow.

Figures 2a-2c schematically illustrate three different reaction conditions for a TMA reaction. When other variables such as enzyme, primer, and NTP concentrations are held constant, under the condition of low input levels of analyte polynucleotide (Figure 2a) the majority of the reaction product is a template-independent nonspecific product (NP) while the analyte amplicon or specific product (SP) represents only a minor component of the total reaction product. Under conditions of high input levels of analyte polynucleotide (Figure 2b), the analyte amplicon (SP) represents a majority of the total reaction product while the nonspecific product (NP) is a minor component. Under conditions where the level of input analyte polynucleotide is low but the level of pseudo target is high (Figure 2c), pseudo target specific product (PTSP) formation is at the expense of nonspecific product formation.

Figures 3a-3b are schematic illustrations showing how inclusion of pseudo targets in idealized reactions that do not produce nonspecific amplification products can transform qualitative assays into quantitative assays. Figure 3a shows how low or high starting levels of analyte polynucleotide (TA) serve as templates for conversion of reactants (R) into similar amounts of analyte-specific products (SP). Figure 3b shows that including pseudo targets (PsT) in amplification reactions having low or high starting levels of analyte polynucleotide results in quantitative relationships between the levels of analyte-specific products synthesized in the reactions and the input levels of templates. The diagram shows that pseudo targets serve as templates in the reaction for the synthesis of pseudo target-specific products (PTSP) while analyte polynucleotides serve as templates for the synthesis of analyte-specific products.

Figures 4a-4d are idealized graphs illustrating how the dynamic range and precision of polynucleotide amplification reactions are improved when the reactions include pseudo targets. Figure 4a shows results be expected for a hypothetical amplification reaction that produces only analyte-specific amplicons. Figure 4b shows results expected for amplification reactions that spontaneously produce low levels of non-specific amplification products that are unrelated to the analyte polynucleotide. Figure 4c shows results expected for amplification reactions that spontaneously produce high levels of non-specific amplification products that are unrelated to the analyte polynucleotide. Figure 4d shows idealized results expected for reactions that include pseudo targets.

Figure 5 is a schematic diagram illustrating how variability in the efficiency of recovery of a collection of polynucleotides that includes an analyte polynucleotide and a pseudo target can yield similar quantities of amplicon following an amplification reaction. The analyte polynucleotide and the pseudo target are shown at the top of the diagram in a fixed starting ratio. Whether 100% or 50% of the polynucleotide sample is input into the amplification reaction, the final amounts of amplicon products are similar.

Figure 6 is a line graph showing how a pseudo target can be used to normalize amplicon synthesis in amplification reactions given different amounts of analyte polynucleotide. The three conditions presented in the graph are: no pseudo target (♦); constant amount of pseudo target (■); and constant ratio of pseudo target and analyte polynucleotide (□).

Figure 7 is a line graph showing how a pseudo target can be used to control the production of analyte amplicons. The two conditions presented in the graph are: no pseudo target (•); and  $2 \times 10^6$  copies of pseudo target per reaction (■).

Detailed Description of the Preferred Embodiment

[0035] Herein I disclose that polynucleotide amplification reactions that included a pseudo target advantageously exhibited improved precision with respect to the amount of analyte amplicon synthesized. Additionally, qualitative amplification reactions can be transformed into quantitative assays by including pseudo targets in the reactions and then quantitatively measuring the amount of analyte amplicon that was synthesized. Also disclosed is a new method of specimen processing which advantageously ensures the production of a preestablished ratio of pseudo target and analyte amplicons in a subsequent amplification reaction, regardless of the efficiency with which nucleic acids were isolated from the specimen. According to this method, pseudo targets are added to a biological specimen before nucleic acids are isolated from the specimen. Assays performed in a qualitative format employing pseudo target amplification, and that provide semi-quantitative information about the amount of analyte polynucleotide in a test sample are also described.

Introduction and Overview

[0036] An observation which led to the development of the invention concerned an inherent feature of the standard TMA reaction. More specifically, it was observed that enzymatic synthesis of nonspecific amplification products represented a substantial proportion of the reaction product when the reaction was initiated using only very low amounts of target polynucleotide. When visualized following electrophoresis, the nonspecific amplification products appeared as a smear that extended over a broad size range. This result is illustrated schematically in Figure 1.

[0037] Importantly, it was observed that TMA reactions carried out using increasing amounts of target polynucleotide templates resulted in diminished relative contributions of the nonspecific products. This result also is illustrated in Figure 1. Reactions that were initiated using higher concentrations of target polynucleotides resulted in the formation of larger amounts of specific products and only small amounts of nonspecific products. This inverse relationship led to speculation that nonspecific reaction product formation could be suppressed by including an amplifiable template in the reaction mixture at the time the reaction was initiated.

[0038] While not wishing to be bound by any particular theory, this inverse relationship may have been particularly noticeable in autocatalytic reactions such as the TMA reaction because, unless interrupted prematurely, the nature of the reaction is to proceed to an end-point where the supply of available reactants is exhausted and no further synthesis can take place. A TMA reaction that proceeds indefinitely in the absence of a target polynucleotide will generate non-specific products until the reactants are depleted and no additional synthesis occurs. A PCR reaction carried out indefinitely is also expected to proceed to a point where the reactants are exhausted and amplicon production ceases, and can also generate nonspecific amplification products (for example, see D. Persing in Diagnostic Molecular Microbiology; Ch 3, p. 58 (1993)).

[0039] As the method disclosed herein is ordinarily practiced, detection of the analyte amplicon is used to indicate the presence of analyte polynucleotides in a population of nucleic acid molecules. For example, a procedure for monitoring the serum level of human immunodeficiency virus (HIV) virions could involve amplifying a portion of the HIV genome and then detecting and quantitating that amplification product. If the procedure further included amplifying a pseudo target, then detection of the pseudo target amplicon would be an optional step that would not be required for success of the assay. Detection of the pseudo target amplicon could be used as a positive control procedure for indicating that an amplification reaction had occurred (i.e., an internal amplification control). However, quantitative characterization of the amount of analyte amplicon synthesized in an amplification reaction, or the quantity of analyte polynucleotide template that would have led to the formation of that amount of analyte amplicon, does not depend on knowledge of the amount of pseudo target amplicon synthesized in the amplification reaction. Thus, analyte amplicon can be quantified according to the methods disclosed herein without reference to the amount of pseudo target amplicon synthesized in an amplification reaction. A critical feature of the method disclosed herein is that the analyte amplicon must be distinguishable from the pseudo target amplicon. More specifically, it must be possible to detect analyte amplicon without also detecting pseudo target amplicon. In a preferred embodiment the analyte amplicon and the pseudo target amplicon differentially bind at least one hybridization probe so that the two amplicon species can be detected independently.

[0040] One point particularly relevant to clinical procedures that employ amplification protocols relates to the variability of recovering polynucleotide templates from different biological specimens. For example, it is common to experience variability in the number of molecules of a given polynucleotide recovered from different tissue samples as the result of variable sample sizes and the complexity of different sample handling procedures. Nucleic acids can bind nonspecifically to glass, plastic and chromatography media such as cross-linked polyacrylamides and dextrans, thereby reducing the efficiency of sample recovery during extensive processing. Additionally, RNA recovered from a biological specimen may have degraded by a variable degree as the result of chemical or enzymatic hydrolysis. Enzymatic hydrolysis is particularly evident in biological samples which contain high concentrations of ribonuclease.

Quantitative Polynucleotide Amplification Assays

[0041] Incorporating a pseudo target into a polynucleotide amplification reaction not only can reduce amplification variability from sample to sample, but also can transform even a fully optimized qualitative assay into a quantitative assay. In the case of a polynucleotide amplification system where only specific amplification products are synthesized (meaning that target nonspecific products are not made) the amount of end product amplified from an initial target polynucleotide would be constant regardless of the starting amount of target polynucleotide included in the reaction. This is true when autocatalytic amplification reactions, such as the TMA reaction, proceed to the point where one of the reactants is depleted sufficiently so that the reaction terminates. The total amount of end product synthesized in this situation is largely determined by the initial concentrations of reactants included in the reaction. Such an optimized polynucleotide amplification system is qualitative but not quantitative when the reaction is carried out to the point where the concentration of one of the reactants becomes limiting. This is because the amount of end product produced in the reaction depends on the starting reactant concentrations and not on the starting amount of polynucleotide target.

[0042] When a pseudo target is included in an amplification reaction, such as a TMA reaction, the pseudo target preferably will be present at a higher copy number relative to the target polynucleotide. The amplification reaction stops when the amount of product amplified from the target polynucleotide and the pseudo target is sufficiently great that one of the reactants has been depleted. Since the pseudo target ordinarily will represent the dominant amplification species, the extent of amplification of the target polynucleotide is determined by the starting amount of the pseudo target and not by the starting amount of the target polynucleotide. Therefore, by controlling the amount of pseudo target in the amplification reaction, the extent of target polynucleotide amplification can be controlled regardless of the starting amount of target polynucleotide in the reaction. While the combined amount of amplification products will be constant when the reactant concentrations are held fixed, the amount of analyte amplicon produced in the reaction will substantially reflect the starting proportion of the analyte polynucleotide relative to the starting level of pseudo target. In this way, a polynucleotide amplification assay can be made into a quantitative assay because the target polynucleotide will amplify by a pre-determined extent. This is illustrated schematically in Figures 2-4.

[0043] In general, the methods for converting qualitative polynucleotide amplification reactions into quantitative reactions by including a pseudo target polynucleotide in the reactions are applicable to all known polynucleotide amplification systems, including PCR, NASBA (nucleic acid sequence-based amplification), SDA (strand displacement amplification), and amplification methods using self-replicating polynucleotide molecules and replication enzymes like MDV-1 RNA and Q-beta enzyme. Methods for carrying out these various amplification techniques respectively can be found in U.S. Patent No. 4,965,188; published European patent application EP 0 525 882, U.S. Patent No. 5,455,166, U.S. Patent No. 5,472,840 and Lizardi et al., *BioTechnology* 6:1197 (1988).

Quantitative Aspects of Amplification Reactions that Include Pseudo Targets

[0044] It is appreciated in the field of nucleic acid testing that polynucleotide amplification is an exponential process and that small differences in any of the variables that affect the reaction rate can lead to dramatic differences in the yield of analyte-specific amplicons. Disclosed herein is the novel finding that non-specific amplification products generated in amplification reactions can significantly contribute to total amplicon production and can consume reactants that otherwise would be used to synthesize analyte-specific amplification products. The contribution of non-specific products to the pool of amplification products is significant enough that small changes in the amounts of non-specific amplification products can profoundly influence the magnitude of analyte amplicon production. Thus, it was discovered during the development of the present invention that reducing the amount of non-specific products formed in an amplification reaction advantageously improved the precision of analyte amplicon production and transformed qualitative amplification assays into quantitative assays.

[0045] The preferred approach for reducing formation of non-specific products requires including a pseudo target in the amplification reaction and then quantitatively detecting analyte amplicons that are synthesized in the reaction. In this way, analyte amplicon production can be related in a dose-dependent fashion to the amount of analyte polynucleotide present at the time the amplification reaction was initiated. Additionally, in accordance with the invented methods it is unnecessary to detect pseudo target amplicons in order to quantify the number of analyte polynucleotides present in a test sample.

[0046] Thus, herein there is disclosed a method of quantifying analyte polynucleotides that does not rely on the detection of amplification products arising from any internal standard. The development of this approach was made possible by recognizing the source of the problem which underlies variability in analyte amplicon production, and which can be controlled by including a pseudo target in the amplification reaction. Although the pseudo target serves as a template in the amplification reaction, detection of pseudo target amplicons is unnecessary for quantifying analyte polynucleotides. While it may seem counterintuitive that precision of an amplification reaction would be improved by adding into the reaction a template that competes with the analyte polynucleotide for reagents needed to synthesize

amplicons, the results presented below clearly demonstrate the value of this procedure. Simply stated, the methods disclosed herein represent a procedure for controlling the otherwise highly variable production of non-specific amplification products by introducing into the system template polynucleotides that are amplified, but that are not necessarily detected or quantified.

5

#### Basis of Improved Precision and Quantitative Capacity of Amplification Reactions

**[0047]** Figures 3a-3b illustrate how pseudo targets can transform a qualitative polynucleotide amplification reaction into a quantitative assay. Figure 3a shows how an optimized reaction converts a pool of reactants (represented in the diagram by an octagon) into specific amplification products (SP) using target analyte (TA) polynucleotides as templates. In the absence of a pseudo target the assay is qualitative because the amount of analyte amplicon produced in the reaction is not quantitatively related to the starting level of target analyte polynucleotide. Whether the starting level of analyte polynucleotide is low or high does not alter the amount of analyte amplicon synthesized in the reaction. Instead, the amount of analyte amplicon that can be produced in the reaction is defined by the starting reactant pool and not by the starting level of analyte polynucleotide. Thus, a constant amount of amplicon is produced when the amplification reaction is carried out to the point of reactant depletion. Conversely, Figure 3b shows how amplification reactions conducted in the presence of pseudo targets synthesize analyte-specific products in proportion to the amount of starting analyte polynucleotide when parallel reactions include a pseudo target. More particularly, when polynucleotide amplification reactions include a pseudo target, the final amount of analyte amplicon is related in a dose-dependent fashion to the starting level of analyte polynucleotide that served as a template in the reaction. Accordingly, it is only necessary to quantify the analyte amplicon (and not the pseudo target amplicon) to gain information about the starting level of analyte polynucleotide in the reaction. This method of quantifying polynucleotides advantageously circumvents the need for detecting amplicons other than the analyte amplicon, or for employing different probes to distinguish different amplicon species. Additionally, the same paired set of oligonucleotide primers can be used to amplify both the analyte polynucleotide and the pseudo target, since the two products of the amplification reaction will be distinguishable using an analyte-specific hybridization probe.

**[0048]** Figures 4a-4d illustrate how analyte amplicon synthesis quantitatively reflects the starting analyte polynucleotide level over an extended range when two competing amplification reactions occur simultaneously. Figure 4a shows results that would be expected for an idealized amplification reaction that takes place in the absence of non-specific product formation. A constant level of analyte amplicon formation is expected at all levels of input analyte polynucleotide. This case reflects the reaction illustrated in Figure 3a. Figure 4b shows results that would be expected for amplification reactions that spontaneously generate non-specific products at low levels. A narrow range of dose-dependency exists only at very low levels of input analyte polynucleotide. Figure 4c shows results that would be expected for amplification reactions that spontaneously generate high levels of non-specific amplification products. In this instance, amplification reactions conducted at any given level of input analyte polynucleotide produce amounts of amplicon falling within a range, as indicated on the Y-axis of the graph. The more significant contribution of the non-specific product formation distinguishes the results shown in Figures 4b and 4c. The breadth of the lines relating the input levels of analyte polynucleotide and analyte amplicon synthesis reflects the low precision of analyte amplicon formation and is attributable to the fact that spontaneous formation of non-specific amplification products can be highly variable. Figure 4d shows results that would be expected for an idealized amplification reaction that includes a pseudo target. The amount of analyte amplicon produced in the reaction exhibits both improved precision and a dose-dependent relationship over a broad range of input analyte polynucleotide levels. This case reflects the idealized reaction illustrated in Figure 3b.

**[0049]** Thus, the precision and quantitative aspects of amplification reactions conducted according to the invented method are interrelated by the existence and controllability of competing reactions wherein analyte and non-analyte polynucleotides co-amplify and compete for reactants. Improved dynamic range results when a second amplification reaction competes with the analyte-specific reaction for reactants. Improved precision in the amount of analyte amplicon synthesis results when the second reaction is made highly controllable by including pseudo targets in the amplification reaction at a level of from  $1 \times 10^3$  -  $2 \times 10^8$  molecules per reaction, where a typical reaction has a volume of 100  $\mu$ l.

50

#### Use of a Standard Curve - Quantifying Pre-Amplification Amounts of Analyte Polynucleotide

**[0050]** Since amplification reactions that include pseudo targets advantageously feature quantitative relationships between the number of analyte polynucleotides input into the reaction and the number of analyte amplicons synthesized, the number of analyte polynucleotides present in a test sample can be determined using a standard curve. More particularly, a plurality of amplification reactions containing constant amounts of pseudo target and known amounts of analyte polynucleotide standard can be run in parallel with an amplification reaction prepared using a test sample containing an unknown number of analyte polynucleotides. Alternatively, a standard curve can be prepared in advance

so that it is unnecessary to prepare a curve each time an analytical procedure is carried out. Such a curve prepared in advance can even be stored electronically in a memory device of a testing instrument. Preferred amplification methods include Transcription Mediated Amplification reactions, NASBA reactions and Polymerase Chain Reactions. Transcription Mediated Amplification is highly preferred. The amounts of pseudo target used should be the same for each reaction and preferably fall in the range of from  $10^3$  to  $2 \times 10^8$ , from  $10^4$  to  $2 \times 10^8$ , from  $10^5$  to  $2 \times 10^8$ , or from  $10^7$  and  $2 \times 10^8$  pseudo target molecules per reaction. Reactions that include pseudo targets can be carried out according to the methods described herein with the number of analyte amplicons synthesized in each reaction being quantified by standard hybridization and detection procedures. Although detection of pseudo target amplicons is unnecessary for quantifying pre-amplification amounts of analyte polynucleotide in the test sample, detection of pseudo target amplicons optionally can be used to confirm success of the amplification reactions. In this way detection of pseudo target amplicons serves as an internal amplification control. A standard curve having pre-amplification amounts of the analyte polynucleotide standard on a first axis and corresponding post-amplification amounts of analyte amplicon on a second axis is then prepared. The post-amplification amount of analyte amplicon measured for the test reaction is then located on the post-amplification axis of the standard curve. The corresponding value on the other axis of the curve represents the pre-amplification amount of analyte polynucleotide that was present in the test reaction. Thus, determining the number of molecules of analyte polynucleotide present in the test sample is accomplished by consulting the standard curve, or more particularly by comparing the quantitative results obtained for the test sample with the standard curve, a procedure that will be familiar to those having an ordinary level of skill in the art.

**[0051]** The procedures described herein can easily be used to quantify analyte polynucleotides present in a test sample. Indeed, if a plurality of pseudo target-containing control amplification reactions are initiated using known numbers of molecules of an analyte polynucleotide standard, and if a test reaction that includes the pseudo target is initiated using an unknown number of analyte polynucleotide molecules, then it becomes possible after quantifying the number of analyte amplicons in each reaction to determine the number of analyte polynucleotide molecules that must have been present in the test sample. For example, if standard reactions that respectively included 500, 1,000 and 1,500 molecules of analyte polynucleotide standard produced analyte amplicon signals of 1x, 2x and 3x following an analyte-specific probe-based hybridization procedure, and if the test sample produced an analyte amplicon signal corresponding to 1.5x, then the test sample must have contained 750 analyte polynucleotide molecules. In this exemplary case a linear relationship exists between the signal generated by the amplicons arising from the analyte polynucleotide standard in the range of from 500 to 1,500 molecules. The relationship between the number of analyte polynucleotide molecules input into the standard amplification reactions and the amplicon-specific signal strength is most conveniently established using a graph. Determining the number of analyte polynucleotide molecules present in a test sample is simply a matter of determining from the standard graph the number of analyte polynucleotide molecules that correspond to a measured analyte amplicon signal strength. This illustrates how analyte polynucleotide standards can be used in connection with pseudo targets in polynucleotide amplification reactions to quantify pre-amplification amounts of analyte polynucleotide contained in test samples.

#### Structural Features of Useful Pseudo Target Polynucleotides

**[0052]** The following information can be used to design pseudo target polynucleotides for use in connection with the methods disclosed herein. Given this information, useful pseudo targets corresponding to any number of analyte polynucleotides that are to be detected and quantified can be made. Exemplary applications where pseudo targets may be used in connection with polynucleotide amplification procedures include, but are not limited to: (1) detecting a bacterial or viral pathogen; (2) quantitating polynucleotides where such quantitation is useful as an indicator of a disease process, such as HIV disease progression; and (3) numerous other applications including forensic analysis, environmental and food testing.

**[0053]** In one preferred embodiment of the invention the pseudo target and the analyte polynucleotide are amplifiable using the same set of two oligonucleotide primers. In this instance, a single oligonucleotide primer that will have a complementary binding site on the pseudo target also will have a complementary binding site on the analyte polynucleotide.

**[0054]** In another preferred embodiment the pseudo target and analyte polynucleotide, which are to serve as templates in an amplification reaction, amplify with substantially similar efficiencies. Thus, whether the amplification is carried out using TMA, PCR or some other procedure such as SDA (strand displacement amplification) or methods employing self-replicating polynucleotide molecules and replication enzymes like MDV-1 RNA and Q-beta enzymes, the pseudo target and analyte polynucleotides preferably will have similar amplification efficiencies.

**[0055]** One way to ensure that the pseudo target and analyte polynucleotide templates will have similar amplification efficiencies is to require that the two templates exhibit closely related, but nonidentical, polynucleotide sequences over the span of the sequence that is amplified in the procedure. For example, a pseudo target polynucleotide may be created by scrambling an internal portion of the sequence of an analyte polynucleotide, where the scrambled sequence

corresponds to the portion of the analyte polynucleotide that serves as the part of the molecule that is hybridized by a probe specific for the analyte polynucleotide. The length of the pseudo target polynucleotide is not critical to its operation in the practice of the methods disclosed herein.

**[0056]** It is essential that the pseudo target and the analyte polynucleotide are co-amplifiable in a single reaction, and that the resulting two amplicon species can be detected independently. More particularly, it is essential that the pseudo target and analyte polynucleotide amplification products have polynucleotide sequences that differ from each other so that the two products can be distinguished by length, by the ability to hybridize to a detection probe, or by other methods. Since the polynucleotide templates amplified in the amplification reactions ordinarily will contain a substantial number of nucleotide bases interposed between the regions homologous or complementary to the primer binding sites used to carry out the amplification reaction, these interposed sequences may serve as regions to which selected hybridization probes can bind. Criteria useful for selecting hybridization and detection probes will be familiar to those having an ordinary level of skill in the art. Probes useful in connection with the invention include labeled polynucleotides as well as oligonucleotides useful as primers in subsequent amplification reactions.

**[0057]** When the pseudo target is added to a biological specimen at a time before analyte polynucleotide is isolated from the specimen, for example as an aid to sample processing, it is important that the pseudo target and the analyte polynucleotide are recoverable from the specimen by the same sample processing procedure. For example, if the analyte polynucleotide is recoverable under strongly alkaline conditions that denature DNA and hydrolyze RNA, then it should also be true that the pseudo target is recoverable as a structurally intact molecule under the same conditions. Thus, if alkaline buffer conditions are used to isolate analyte polynucleotides in the presence of added pseudo target polynucleotides, then neither the analyte nor the pseudo target would be an RNA molecule that would be degraded during the isolation procedure. Similarly, if the pseudo target and the analyte polynucleotide are to be precipitated, for example by the addition of an alcohol such as ethanol, then the pseudo target and the analyte polynucleotide should precipitate with substantially similar efficiencies.

## 25 Relationship between Pseudo Target and Analyte Polynucleotide Sequences

**[0058]** Significantly, it is preferred but not essential for the pseudo target and the analyte polynucleotide to be co-amplifiable using the same set of two oligonucleotide primers. More specifically, qualitative polynucleotide amplification assays for detecting an analyte polynucleotide using a paired set of analyte-specific primers can be transformed into quantitative assays by further including in the reaction a pseudo target and a set of primers for amplifying the pseudo target. In one embodiment of the invented method, the analyte polynucleotide and the pseudo target are co-amplifiable using the same two primers.

**[0059]** It is also possible to employ a "universal pseudo target" and a set of pseudo target-specific primers to produce quantitative amplification reactions. In one embodiment of the invention, the primers used for amplifying the universal pseudo target can be the same as the primers used for amplifying the analyte polynucleotide. The universal pseudo target need not be related to the structure of the analyte polynucleotide, and need not co-amplify with the analyte polynucleotide with similar amplification efficiency. Amplification reactions conducted using low or high starting levels of analyte polynucleotide will synthesize analyte amplicons in a fashion that is dose-dependent on the starting amounts of analyte polynucleotide present when the amplification reactions were initiated. Using this procedure, two or more amplification reactions can be assessed for the production of analyte amplicons, with the analyte amplicon levels being related to the starting levels of analyte polynucleotide in each sample in a dose-dependent manner.

**[0060]** While good results can be achieved using pseudo targets and associated primers that are unrelated to the analyte polynucleotide, it is preferable to employ pseudo targets that co-amplify with the analyte polynucleotide using the same set of primers. This preferred approach advantageously reduces variability in the composition of the reagent pool used as a resource for synthesizing amplicons in the amplification reaction. However, the illustrative Examples presented herein for describing the invention employ pseudo targets and exemplary analyte polynucleotides that co-amplify using common sets of oligonucleotide primers.

## Choosing an Amount of Pseudo Target to be Included in an Amplification Reaction

**[0061]** In general, the positive benefits achieved by including pseudo targets in polynucleotide amplification reactions are achievable over a very broad range of pseudo target concentrations. More particularly, including pseudo targets in amplification reactions, such as TMA reactions, in amounts ranging from  $1 \times 10^3$  -  $2 \times 10^8$  molecules will result in: (1) higher precision of amplification, (2) reduced likelihood of positive carryover and (3) normalization of target recovery variability, all as disclosed herein. Within practical limits, higher starting levels of pseudo target in an amplification reaction will result in greater improvement of the three above-referenced parameters.

**[0062]** Since pseudo target amplicons will be synthesized using nucleotide triphosphate reactants that otherwise could be used to synthesize analyte amplicons, the presence of a pseudo target in an amplification reaction will result

in a reduction of the synthesis of analyte amplicons. This is because both analyte amplicons and pseudo target amplicons are synthesized from a limited pool of reactants. Accordingly, increasingly high starting levels of pseudo target will result in decreasing amounts of analyte amplicon produced in the amplification reaction. Thus, the upper limit of starting pseudo target concentration in an amplification reaction will be a practical matter dependent on the sensitivity of the procedure used for detecting the analyte amplicon.

**[0063]** The upper limit amount or concentration of a pseudo target that can be included in an amplification reaction, and that will yield levels of analyte amplicon adequate for detection, is most easily determined by routine experimentation. Again, it will be readily apparent to those having ordinary skill in the art that higher levels of pseudo target in an amplification reaction conducted to the point of reagent exhaustion will result in lower amounts of analyte amplicon produced in the reaction. This is because pseudo target amplicons are synthesized at the expense of analyte amplicons in the amplification reaction. Thus, amplification reactions that include very high levels of a pseudo target will result in the production of low levels of analyte amplicon. Highly sensitive assays for detecting analyte amplicons will be particularly useful for detecting these lower levels of analyte amplicon. Conversely, less sensitive assays that require larger amounts of analyte amplicon for a positive detection signal will be useful for detecting larger quantities of analyte amplicon that might result from amplification reactions that included only low starting levels of pseudo target, and that resulted in higher levels of analyte amplicon. Thus, the upper limit of the amount of pseudo target that can be used for conducting an amplification reaction will depend on the sensitivity of the assay that is ultimately to be used for detecting analyte amplicons, and not on the amplification reaction itself.

**[0064]** Since it is generally true that higher levels of input pseudo target provide enhanced reduction of nonspecific amplification products in reactions such as the TMA reaction, it follows that the amount of pseudo target included in an amplification reaction preferably should be as high as possible. The highest pseudo target level disclosed in the Examples which follow was  $2 \times 10^8$  molecules in a 100  $\mu\text{l}$  reaction. Of course, the detection system used for detecting analyte amplicons must be sensitive enough to give a positive signal when analyte polynucleotides are present in the starting sample so that analyte amplicons are synthesized in the amplification reaction. In practice, a range of pseudo target concentrations can be tested to identify an optimal amount that gives good results in the amplification reaction as measured by detectability of analyte amplicons using a detection system having a given sensitivity for detecting analyte amplicons. Ordinarily, positive and negative controls will be included in this procedure to indicate the results that would be expected for amplification reactions that did or did not include analyte polynucleotides, respectively.

**[0065]** The amount of pseudo target selected for conducting an amplification reaction can be influenced by the magnitude of the amplification, the starting number of analyte polynucleotides in the reaction and on the sensitivity of the detection system used for detecting analyte amplicons. Standard TMA reactions typically amplify starting polynucleotide levels by  $10^{12}$  -  $10^{13}$  fold. An exemplary polynucleotide detection system can detect approximately  $6 \times 10^7$  molecules in a hybridization assay. In order to detect 100 molecules of an analyte polynucleotide in a sample that served as the source of templates in an amplification reaction, it would be necessary to achieve an amplification of approximately  $6 \times 10^5$  fold ( $6 \times 10^7$  divided by 100). To achieve at least  $6 \times 10^5$  fold amplification of the 100 analyte polynucleotide molecules the amplification reaction should not include more than  $1 \times 10^7$  pseudo target molecules. This is because  $6 \times 10^{12}$  (as an example value in the range of from  $10^{12}$  -  $10^{13}$  fold as indicated above) divided by  $1 \times 10^7$  equals a  $6 \times 10^5$  fold increase. Including a greater number of pseudo target molecules would reduce the fold amplification to less than the acceptable  $6 \times 10^5$  value. If instead a PCR protocol leading to a  $1 \times 10^9$  fold amplification were employed, the maximum acceptable amount of pseudo target in the amplification reaction would be  $1 \times 10^9$  divided by  $6 \times 10^5$ , or  $1.7 \times 10^3$  molecules. Thus, it should be clear that: (1) a broad range of pseudo target concentrations will be useful in the practice of the method disclosed herein, and (2) an optimal amount of pseudo target can be determined empirically when the number of analyte polynucleotides in a sample being tested in an amplification protocol is unknown.

**[0066]** Preferred amounts of pseudo target useful for conducting amplification reactions typically range from between  $10^3$  and  $10^9$  molecules per reaction, where a typical reaction is conducted in a 100  $\mu\text{l}$  volume. For example, an assay for detecting HIV polynucleotides in a serum sample isolated from an HIV-infected human can be conducted using between  $10^3$  and  $2 \times 10^8$ , between  $10^4$  and  $2 \times 10^8$  or between  $10^5$  and  $2 \times 10^8$ , or between  $10^7$  and  $2 \times 10^8$  pseudo target molecules per reaction. In a highly preferred embodiment, the amplification reaction is a TMA reaction and the HPA ("homogenous protection assay") method is used for detecting analyte amplicons produced in amplification reactions conducted using these amounts of pseudo target. As indicated in the Examples which follow, broad ranges of pseudo target concentrations have been tested and shown to give good results.

#### Kits for Performing the Invented Method of Polynucleotide Amplification

**[0067]** Kits useful for performing the polynucleotide amplification methods described herein will include: (1) a pseudo target, (2) oligonucleotide primers for co-amplifying the pseudo target and the analyte polynucleotide, (3) reagents for carrying out the polynucleotide amplification reaction, and (4) printed instructions for carrying out an amplification reaction and for specifically detecting only analyte amplicons produced in the reaction. Optionally the kit may include

a labeled probe for detecting analyte amplicons. Reagents included with the kit will comprise deoxyribonucleotide triphosphates and a DNA polymerizing enzyme, which may be a reverse transcriptase. Nucleotide triphosphates and an RNA polymerase are optional reagents that can be included in the kit.

[0068] With this background, three particular aspects of the invention now are described in more detail.

5

## I. Enhancing the Precision of Analyte Polynucleotide Amplification

[0069] Amplification techniques, both quantitative and qualitative, represent powerful tools for detecting and measuring even trace amounts of specific target polynucleotides. However, difficulty in obtaining uniform amplification efficiency among different reactions means that variability in the extent of amplification compromises the precision of quantitation and the ability to detect small amounts of target. I sought to develop methods that could minimize the formation of nonspecific products, enhance precision in the amount of analyte amplicon synthesis and maximize the ease with which quantitative amplification reactions could be performed.

[0070] Variability in the extent of amplification appears to be partly attributable to the enzymatic synthesis of non-specific reaction products. The formation of these nonspecific products was most noticeable when reactions contained only very low starting levels of target polynucleotides that served as amplification templates. At higher levels of target polynucleotide, the formation of nonspecific reaction products was less significant and represented only a small proportion of the total product of the reaction. Thus, an object of the present invention was to simulate reaction conditions that were characteristic of high target polynucleotide concentrations even when starting levels of analyte polynucleotides in the reaction mixtures were very low. More particularly, it was desirable to simulate favorable reaction conditions that would minimize the formation of nonspecific products, as represented in Figure 2.

[0071] Amplification reactions supplemented with pseudo target polynucleotides that co-amplified with the analyte polynucleotide provided the desired reaction conditions to achieve these objectives. This allowed the amplification reaction to behave as if high levels of analyte were present even when the true analyte level in the amplification reaction was low. As indicated by experimental results presented below, adding greater than  $10^5$  copies of the pseudo target polynucleotide improved amplification precision as measured by an improved coefficient of variability (CV%) of relative light units (RLUs), where RLUs represent a measurable indicator of the quantity of hybridized probe. In the present context, CV% is a statistical value that is calculated by dividing the standard deviation (SD) for a collection of data by the net average for that collection and then multiplying the result by 100. Lower CV% values reflect less spread among data points and are taken as indicators of higher experimental precision. Thus, the method described herein provides a way to improve the precision with which the analyte polynucleotide is amplified while reducing the formation of variably sized nonspecific reaction products.

[0072] The methods disclosed herein additionally provide a mechanism for standardizing the results of polynucleotide amplification reactions regardless of the starting level of analyte polynucleotide as long as the analyte polynucleotide was present at a copy number lower than the copy number of the pseudo target. In an exemplary procedure described below, analyte polynucleotide was present in a set of amplification reaction mixtures at starting levels of from  $10^1$ - $10^5$  molecules while the pseudo target was present in all mixtures at  $10^6$  molecules. This meant that all the amplification reactions were initiated from substantially  $10^6$  polynucleotide templates because the contribution of the analyte polynucleotides to the total number of templates in any of the mixtures was minimal. Thus, all of the amplification reactions behaved as though they contained roughly  $10^6$  templates even though the number of analyte polynucleotides varied widely. This effectively standardized the amplification reactions to  $10^6$  template polynucleotides regardless of actual analyte level.

## II. Controlling Amplicon Production

[0073] It has been further discovered that pseudo targets can be employed to overcome obstacles associated with the "over production" of analyte amplicons that can lead to inaccurate quantitation of high levels of input target polynucleotide. If excessive amounts of amplicon are produced in an amplification reaction, and if those amplicons are to be quantitated by hybridizing a detection probe to saturation, then large quantities of detection probe necessarily will be consumed in the detection step of the assay. Conversely, if reduced levels of amplicon are produced, then less detection probe will be required to carry out the detection step. Still another advantage of reducing the amount of amplicon produced in an amplification reaction relates to the another aspect of the detection apparatus used for detecting the amplicon. Since detection means such as luminometers often will have linear response ranges that can be saturated at high signal levels, it is an advantage to be able to conduct amplification reactions such that the signal produced in a detection step falls within the linear response range for the detection apparatus. Thus, the ability to control amplicon synthesis clearly is beneficial with respect to subsequent detection steps.

[0074] The amount of analyte amplicon generated in the amplification reaction can be controlled by including a pseudo target in the amplification reaction to compete with the target polynucleotide for amplicon synthesis. When the

5 pseudo target is present, reactants in the amplification reaction mixture will be used to synthesize both analyte amplicons and pseudo target amplicons. If the amplification reaction proceeds to reagent exhaustion, and if higher numbers of pseudo target amplicons are produced at the expense of analyte amplicons, then the relative proportion of analyte amplicons can be reduced by increasing the starting amount of pseudo target in the amplification reaction. An appropriate level of pseudo target to be included in the amplification reaction can be determined using no more than routine experimentation.

10 [0075] An alternative approach to reducing analyte amplicon production in a polynucleotide amplification reaction such as the TMA reaction would be to perform the reaction under sub-optimal conditions, such as those described in U.S. Patent Nos. 5,705,365 and 5,710,029. This alternative may at times be less desirable than the above-described approach because different conditions may be required to "de-optimize" the reaction for different analytes to be detected. In contrast, reducing the amount of analyte amplicon produced in a reaction by including a pseudo target allows all reactions to be performed under optimal conditions.

15 [0076] Thus, including a pseudo target in an amplification reaction provides a means for "tuning" a quantitative amplification reaction by competing high target levels with even higher levels of pseudo target.

### III. Specimen Processing in the Presence of Added Pseudo Targets

20 [0077] Uniform recovery of target polynucleotides from different biological samples is very important for many quantitative assays. For example, assays for determining plasma levels of HIV virions easily could lead to an inaccurate estimation of virion levels in the plasma if the precision of target polynucleotide recovery is low. Herein there is described an alternative approach that is relatively tolerant to variability in the level of input analyte polynucleotides.

25 [0078] Rather than striving for quantitative recovery of polynucleotides that will serve as templates in an amplification reaction, one aspect of the invention is directed to a method of normalizing variability of target polynucleotide recovery at the specimen processing step. According to this approach, the final amount of a target polynucleotide amplification product is easily controlled when the level of a pseudo target is sufficiently high that pseudo target amplification competes with true target amplification and when the pseudo target and the analyte polynucleotide are co-amplifiable with similar amplification efficiencies. In this range, the amount of analyte amplicon is inversely proportional to the input level of the pseudo target. For example, if the input level of pseudo target is increased by  $X$  fold, then the analyte amplicon will be reduced to  $1/X$ . When pseudo target is present in specimen processing steps, the pseudo target and the true target will be recovered with similar efficiencies. Therefore, if the recovery efficiency for the analyte polynucleotide is  $K\%$ , then the pseudo target also will be recovered at an efficiency of  $K\%$ .

30 [0079] Under otherwise identical conditions, reactions will produce a relatively constant amount of amplicon. Thus, addition of pseudo target diverts the reaction components from making nonspecific amplicon and ensures that effectively all of the amplicon produced in the reaction is either pseudo target amplicon or analyte amplicon representing the amplification product of an analyte polynucleotide. The pseudo target amplicon and the analyte amplicon will be produced in the same ratio as the ratio of pseudo target and analyte polynucleotide at the time the amplification reaction was initiated.

35 [0080] When analyte polynucleotides and pseudo targets are co-isolated and then added to an amplification reaction that proceeds to reactant exhaustion, the relative proportion of resulting analyte and pseudo target amplicons will be the same as the relative proportion of analyte and pseudo target polynucleotides in the sample isolated from the biological specimen. This means that, regardless of the efficiency of the polynucleotide recovery in specimen processing, the amount of analyte amplicon synthesized in an amplification reaction will be the same as the amount that would have been synthesized if 100% of the analyte polynucleotide and pseudo target had been recovered in the specimen processing step. Thus, by adding a pseudo target to a biological specimen at the time of processing to isolate polynucleotides for subsequent amplification, the target recovery efficiency will be normalized in the subsequent amplification step.

#### Amplification Reactions that Include Pseudo Targets

50 [0081] Two convenient formats can be used for performing the TMA reactions that were employed in Examples described below. In the first format, all materials are in a liquid state at all times. For example, solutions of reagents, templates and enzymes are combined in a reaction vessel and the amplification is allowed to proceed. This is most convenient when the target polynucleotide is available in a purified or semi-purified state. In the second format, the polynucleotide template to be amplified in the TMA reaction is first collected on a solid phase (such as a bead), and the complex that includes the solid phase and the template combined with other reagents in the amplification reaction. Useful solid phase supports include but are not limited to nitrocellulose, nylon, glass, coated magnetic particles, polyacrylamide, polystyrene and derivatized polymers such as epoxies. This second format is especially convenient when the template polynucleotide is available in limiting amounts. Those having an ordinary level of skill in the art will ap-

preciate that manipulating small samples of polynucleotides easily can be replaced by manipulating suspensions of the larger and more manageable beads. Moreover, the beads may represent one component in a scheme for purifying the template. For example, beads having an oligo(dT) polynucleotide disposed thereon can be mixed with a cell lysate such that poly(A)<sup>+</sup> mRNA becomes immobilized on the beads. Thus, the complex that includes the beads and immobilized mRNA can be combined with reagents and enzymes so that a TMA reaction can be performed using the RNA joined to the beads as templates for the amplification. Under this circumstance the beads may be added directly to the reaction vessel. If instead of an oligo(dT) polynucleotide a polynucleotide having a different sequence is immobilized onto beads, that different sequence can be used to capture a complementary analyte polynucleotide or pseudo target from a collection of polynucleotides. This method of immobilizing a particular polynucleotide to a solid support can provide a means for isolating particular polynucleotides from a complex mixture of polynucleotides. Other methods of isolating polynucleotides can involve standard procedures such as extraction with organic reagents such as mixtures of phenol and chloroform, optionally including alcohol precipitation steps.

**[0082]** The following Examples demonstrated that the presence of pseudo targets advantageously reduced variability of amplicon production in TMA reactions that included magnetic beads derivatized with oligo(dT). This decreased variability alternatively can be expressed as an increase in the "precision" of amplification. More particularly, the results presented below demonstrated that different reactions performed using substantially identical amounts of starting template polynucleotides advantageously gave more reproducible results where variability from sample to sample was reduced.

**[0083]** Although many different methods of detecting amplified polynucleotides can be used in connection with the present invention, the "Hybridization Protection Assay" (HPA) disclosed in U.S. Patent No. 5,639,604 represents a particularly useful method. In one embodiment, the HPA detection method involves hybridizing amplified polynucleotides with a complementary polynucleotide probe that is labeled with a chemiluminescent acridinium ester. When hybridized in a duplex structure, the acridinium ester is protected from degradation under mild hydrolysis conditions. Acridinium ester in unhybridized probe molecules is susceptible to such degradation and is selectively destroyed by appropriate chemical treatment. Determining the amount of undegraded acridinium ester indicates the amount of probe that was hybridized to complementary polynucleotides. This determining step involves adding hydrogen peroxide to the mixture and measuring the amount of light emitted during a subsequent base-catalyzed chemiluminescence reaction. The HPA method of quantitating amplicon synthesis is preferred because there is no requirement for tedious and time consuming steps to remove excess unhybridized probe which otherwise would result in high levels of background hybridization. However, other methods for detecting and quantifying amplicons, such as procedures that employ radioactive, fluorescent or enzyme-labeled probes or other detection methods which use separation methods including but not limited to solid-phase support formats, HPLC and electrophoresis, can be used in the practice of the invented method with equally good results. Indeed, the method used to detect amplicons is not expected to influence the quality of the results that would be obtained in the following procedures.

### Preferred Analyte Polynucleotides

**[0084]** As described herein, quantitative methods employing pseudo targets can be used for conducting amplification reactions regardless of the origin of the analyte polynucleotide. Preferred analyte polynucleotides include nucleic acids from disease-causing organisms, including viruses, bacteria, fungi and protozoa. Examples of highly preferred analyte polynucleotides from viruses are nucleic acids from the human immunodeficiency viruses (HIV-1 and HIV-2), the hepatitis B virus (HBV), and the hepatitis C virus (HCV). Preferred analyte polynucleotides from bacteria, fungi and protozoa that can be quantitated according to the methods disclosed herein include the ribosomal RNAs (rRNA). Examples of bacteria that are highly preferred as sources of analyte polynucleotides include *Chlamydia trachomatis* (Gram-negative cells that are obligate intracellular organisms), members of the genus *Campylobacter* (*C. jejuni*, *C. coli*, *C. laridis*), members of the genus *Enterococcus* (*E. avium*, *E. casseliflavus*, *E. durans*, *E. faecalis*, *E. faecium*, *E. gallinarum*, *E. hirae*, *E. mundtii*, *E. pseudoavium*, *E. malodoratus*, and *E. raffinosus*), *Haemophilus influenzae*, *Listeria monocytogenes*, *Neisseria gonorrhoeae*, *Staphylococcus aureus*, *Group B Streptococci*, *Streptococcus pneumoniae*, *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium intracellulare*, *Mycobacterium gordonae*, *Mycobacterium kansasii*. Examples of fungi that are highly preferred as sources of analyte polynucleotides include: *Blastomyces dermatitidis*, members of the genus *Candida* (*C. albicans*, *C. glabrata*, *C. parapsilosis*, *C. diversus*, *C. tropicalis*, *C. guilliermondii*, *C. dubliniensis*), *Histoplasma capsulatum*, *Coccidioides immitis*. Examples of protozoa that are highly preferred as sources of analyte polynucleotides include blood and tissue protozoa, such as members of the genus *Plasmodium* (*P. malariae*, *P. falciparum*, *P. vivax*), as well as protozoa which infect the gastrointestinal tract such as *Giardia lamblia* and *Cryptosporidium parvum*.

**[0085]** The invented method also can be used for quantifying nucleic acids that are of human origin, such as mRNAs that are over-expressed or under-expressed in disease states, including cancers. One example of gene that is present at an increased copy number in breast and ovarian adenocarcinomas is the HER-2/neu oncogene which encodes a

tyrosine kinase having certain features in common with the epidermal growth factor receptor (EGFR). U.S. Patent No. 4,968,603 describes the value of measuring the increased copy number of the HER-2/neu gene, or the HER-2/neu mRNA as a tool for determining neoplastic disease status. Thus, for example, the method described herein can be employed in quantitative nucleic acid amplification protocols whereby the cellular content of HER-2/neu polynucleotides is determined.

[0086] Indeed, the polynucleotide amplification method described herein is broadly applicable to numerous nucleic acid targets and is easily extended to procedures for quantifying any given analyte polynucleotide in a test sample.

[0087] Although other materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. General references for methods that can be used to perform the various nucleic acid manipulations and procedures described herein can be found in *Molecular Cloning: A Laboratory Manual* (Sambrook, et al. eds. Cold Spring Harbor Lab Publ. 1989) and *Current Protocols in Molecular Biology* (Ausubel, et al. eds., Greene Publishing Associates and Wiley-Interscience 1987). Methods of performing the TMA reaction are disclosed in U.S. Patent No. 5,399,491. Improvements to the TMA reaction protocol, such as that disclosed in U.S. Patent No. 5,786,183, are embraced within the scope of Transcription Mediated Amplification for the purpose of the present disclosure. Methods of preparing and using acridinium ester labeled probes are given by Arnold et al., in U.S. Patent No. 5,639,604. A description of the experiments and results that led to the creation of the present invention now follows.

[0088] Example 1 describes methods which demonstrated that polynucleotide amplification reactions which included a pseudo target showed reduced variability of amplicon production.

## Example 1

### Pseudo Target Amplification Reduces Variability in the Quantity of Amplicon Produced in TMA

[0089] A series of TMA reactions was prepared using primers specific for a segment of the HIV *pol* transcript. All reactions were performed in replicates of eight. Each reaction received: 50  $\mu$ l containing 60 copies of RNA transcripts of the complete HIV genome diluted in specimen buffer consisting of 10 mM HEPES (pH 7.5) and 1 mM EDTA. The RNA transcript had been synthesized using the plasmid BH10 as a template. In this procedure, the BH10 RNA was used as an exemplary analyte polynucleotide. The polynucleotide sequence of the BH10 RNA is given by the sequence of SEQ ID NO:3. Reactions also included either 0, 10<sup>5</sup>, 10<sup>6</sup> or 10<sup>7</sup> copies of the IAC-Ascr pseudo target RNA having the sequence of SEQ ID NO:4. There were added 25  $\mu$ l of amplification reagent containing 10 pmols of a T7A(-)4190 primer having the sequence AATTAAATACGACTCACTATAGGGAGAGTTGTATGTCTGTTGCTATTATGTCTA (SEQ ID NO:1); 10 pmols of the (+)4108 primer having the sequence ACAGCAGTACAATGGCAG (SEQ ID NO:2); 160 mM Tris buffer (pH 7.5); 16 mM each of ATP, CTP, GTP and UTP; 4 mM each of dATP, dCTP, dGTP and dTTP; 100 mM MgCl<sub>2</sub>; 70 mM KCl; 20% glycerol; 0.6 mM zinc acetate and 20% polyvinylpyrrolidone. Samples were then overlaid with 200  $\mu$ l of mineral oil, incubated first at 65°C for 10 minutes to allow primer-target annealing, and then incubated at 42°C for 5 minutes. Thereafter, each reaction received a 25  $\mu$ l aliquot of enzyme mixture that contained 2,000 GP units of MMLV reverse transcriptase; 2,000 GP units of T7 RNA polymerase; 140 mM Tris buffer (pH 8.0); 100 mM N-acetyl-cysteine as a reducing agent; 20% glycerol; 70 mM KCl; 80 mM trehalose; 8 mM HEPES; 1.04 mM EDTA; 10% TRITON X-102 and 0.01% phenol red. One GP unit of reverse transcriptase corresponds to the amount of enzyme that synthesizes 5.75 fmols of cDNA from an RNA template in 15 minutes at 37°C. One GP unit of RNA polymerase is defined as the amount of enzyme that synthesizes 5 fmols of RNA transcript from a double stranded DNA template containing a promoter sequence in a period of 20 minutes at 37°C. Reactions were incubated at 42°C for an additional 60 minutes. Thereafter, 100  $\mu$ l samples of the reaction mixtures were combined with an equal volume of the HIV-specific AE(+) 4134 probe bearing an acridinium ester moiety as the label and having the sequence CCACAATTAAAGAAAAG-GGGGGATTGG (SEQ ID NO:5). This labeled polynucleotide probe was prepared and used essentially according to the method disclosed in U.S. Patent No. 5,639,604 and dispersed in a solution that included 100 mM lithium succinate buffer (pH 4.7), 2% (w/v) lithium lauryl sulfate, 1.2M lithium chloride, 15 mM aridithiol-2, 20 mM EDTA, 20 mM EGTA and 3% ethanol. Substantially all of the ionic strength for promoting the hybridization reaction was provided by the 600 mM lithium chloride and 1% lithium lauryl sulfate components of the final hybridization solution. Importantly, the sequence of the AE(+)4134 probe permitted hybridization through complementary base pairing only with the analyte amplicon and not with the pseudo target amplicon. After hybridizing the mixture at 60°C for 15 minutes, 300  $\mu$ l of a selection reagent containing 600 mM sodium borate (pH 8.5) and 1% TRITON X-100 was added and the mixture incubated at 60°C to inactivate unhybridized probe. Finally, the mixtures were cooled to room temperature, placed into a luminometer and the amount of analyte amplicon quantitated by measuring the light emitted from a chemiluminescent reaction (in RLUs). Detection reagent I included hydrogen peroxide solution in 0.001 N nitric acid. Detection reagent II included 1 N NaOH solution. Each reaction tube was injected first with detection reagent I, then with detection reagent II in order to stimulate light emission. Notably, probes used to detect and quantify the analyte amplicon were as follows:

reactions not receiving the pseudo target were probed with 100 fmols of labeled AE(+)4134 probe (SEQ ID NO:5) and 3.9 pmols of unlabeled 2'methoxyribonucleotide (2'OMe) (+)4134; reactions that included  $10^5$  copies of the pseudo target were probed using 100 fmols of labeled probe and 3.9 pmols of unlabeled 2'OMe (+)4134; reactions that included  $10^6$  copies of the pseudo target were probed using 100 fmols of labeled probe and 0.2 pmols of unlabeled 2'OMe (+)4134; reactions that included  $10^7$  copies of the pseudo target were probed using 100 fmols of labeled probe alone. Notably, 2'OMe has substituted a methoxy moiety for the hydroxyl moiety at the 2' position of the ribose in RNA. It should be noted that the (+)4134 polynucleotide had the same base sequence as the AE(+)4134 polynucleotide, but did not include the N-acridinium ester label. The different probe specific activities were employed to facilitate luminometry readings in a linear detection range.

**[0090]** The results presented in Table 1 indicated that amplification reactions which included a pseudo target advantageously gave more uniform results with less variability among the collection of samples. Table 1 shows the number of copies of IAC-Ascr pseudo target and BH10 RNA analyte polynucleotide included in each reaction. Also shown are the raw data representing the light emission from the reactions (in RLUs) and the net emission which has been corrected to subtract out the background emission measured in the negative control reactions. The column marked "Corrected to Uniform Sp. Act." indicates the value of the net RLUs that would be obtained if all HPA assays had been performed using the same high specific activity probe. This value was included in the analysis so that the different reactions could be compared directly. The net averages of all determinations for a given reaction condition are also presented along with the calculated values for standard deviation (SD) and coefficient of variability (CV%). The last column in the Table shows that the CV% values decreased as the number of copies of pseudo target in the reactions increased. This result quantitatively indicated that variability in the amount of amplicon produced in different reactions decreased as the amount of pseudo target was increased.

TABLE 1

Pseudo Target Amplification and Analyte Amplicon Synthesis Using Soluble Polynucleotides (Pure System)								
	IAC-Ascr (copies)	BH10 RNA	RLUs	net RLUs	Corrected to Uniform Sp. Act.	net Avg.	Standard Deviation (SD)	Coefficient of Variability (CV%)
		60758	55366	2214640				
		100316	94924	3796960				
		116898	111506	4460240				
		80682	73500	3012000				
25	None	60	78084	72692	2907680	2340305	1465936	62.6
30			31443	26051	1042040			
			29419	24027	961080			
35			13587	8195	327800			
40	None	5392	0	0	0			
		85700	78257	3130280				
		64487	57044	2281760				
45			54852	47409	1896360			
			41357	33914	1356560			
50	$1.0 \times 10^5$	60	51353	43910	1756400	3029790	1891104	62.4
			93974	86531	3461240			
			190926	183483	7339320			
55			82853	75410	3016400			
	None	7443	0	0	0			
		580816	572789	1718367				
		401651	393624	1180872				

TABLE 1 (continued)

Pseudo Target Amplification and Analyte Amplicon Synthesis Using Soluble Polynucleotides (Pure System)								
	IAC-Ascr (copies)	BH10 RNA	RLUs	net RLUs	Corrected to Uniform Sp. Act.	net Avg.	Standard Deviation (SD)	Coefficient of Variability (CV%)
5			302690	294663	883989			
10			222165	214138	642414			
15	1.0 x 10 <sup>6</sup>	60	275810	267783	803349	1036444	323123	31.2
20			322421	314394	943182			
25			349792	341765	1025295			
30			372722	364695	1094085			
	None		8027	0	0	0		
			155174	146863	146863			
			138647	130336	130336			
			102893	94582	94582			
			157291	148980	148980			
	1.0 x 10 <sup>7</sup>	60	166824	158513	158513	134795	30825	22.9
			149727	141416	141416			
			181812	173501	173501			
			92482	84171	84171			
	None		8311	0	0	0		

**[0091]** Example 2 describes the methods used to demonstrate that enhanced precision of amplicon production was a general feature of reactions that included a pseudo target. More particularly, the following procedures showed that a second exemplary pseudo target, called IAC-Bscr, also reduced the variability of amplicon production in an exemplary TMA reaction.

## Example 2

### Reduced Variability in the Production of Analyte Amplicons by TMA is a General Feature of Reactions that Included a Pseudo Target

**[0092]** 30  $\mu$ l containing 60 molecules of BH10 RNA diluted in specimen buffer (1 mM EDTA, 10 mM HEPES) was added to a series of reaction tubes. 20  $\mu$ l containing 0, 10<sup>5</sup>, 10<sup>6</sup>, 10<sup>7</sup> or 10<sup>8</sup> IAC-Bscr pseudo target RNA molecules (SEQ ID NO:9) in specimen buffer was added to appropriate tubes. After vortexing, each tube received a 25  $\mu$ l aliquot of amplification reagent described in Example 1, with the exception that the concentrations of the T7A(-)4190 and (+) 4108 primers were used at 5 pmols each instead of 10 pmols. The liquid contents of each tube were then overlaid with 200  $\mu$ l of oil to prevent evaporation. Tubes were incubated at 65°C for 10 minutes and then at 42°C for 5 minutes. A 25  $\mu$ l aliquot of enzyme reagent as described in Example 1 was subsequently added to each tube. The contents of all tubes were mixed and the reactions incubated at 42°C for 1 hour. At the end of the reaction period, all samples were subjected to analysis by standard HPA. Accordingly, 100  $\mu$ l of a solution of acridinium labeled 2'methoxy AE(+)4134 probe was added to each tube. Different specific activities of the probe were used to detect analyte amplicons in samples produced using different amounts of the IAC-Bscr pseudo target. This ensured that light emission readings in the detection procedure would fall within the linear range of the luminometer that was used for quantifying analyte amplicons. Probes used to detect and quantify the analyte amplicon were as follows: reactions not receiving the pseudo target were probed with 100 fmols of labeled 2'OMe(+)4134 probe and 20.0 pmols of unlabeled probe; reactions that included 10<sup>5</sup> copies of the pseudo target were probed using 100 fmols of labeled probe and 3.0 pmols of unlabeled probe; reactions that included 10<sup>6</sup> copies of the pseudo target were probed using 100 fmols of labeled probe and 0.4 pmols of unlabeled probe; reactions that included 10<sup>7</sup> or 10<sup>8</sup> copies of the pseudo target were probed using 100 fmols

of labeled probe alone. Mixtures of the amplification products and the probe were incubated at 60°C for 15 minutes, mixed with 300  $\mu$ l of selection reagent and then incubated at 60°C for an additional 10 minutes. The mixtures were cooled to room temperature and chemiluminescence was read after adding detection reagents 1 and 11.

**[0093]** The results presented in Table 2 confirmed that amplification reactions that included a pseudo target advantageously produced more uniform amounts of analyte amplicon with less variability among the collection of sample readings. Table 2 shows the number of copies of IAC-Bscr pseudo target and BH10 RNA analyte polynucleotide that were included in each of 8 replicate amplification reactions that were conducted for each level of input pseudo target. Also shown are the results representing the average net light emission readings from all HPA reactions. Background emission values measured for reactions that included the pseudo target without including the model analyte polynucleotide were subtracted to obtain the net results. The average amounts of analyte amplicon produced for each reaction condition ("Amplicon") are presented so that the products of different HPA reactions hybridized with probes having different specific activities could be compared directly. Also presented are values for standard deviation (SD) and coefficient of variability (CV%) that were calculated for all luminometry determinations for a given reaction condition. The results confirmed that the amounts of analyte amplicon synthesized in reactions that included a pseudo target were produced with greater precision than in reactions that did not include a pseudo target. More particularly, reactions that were conducted using greater than  $1 \times 10^5$  pseudo target molecules yielded CV% values that were lower than the CV% value obtained for the data set produced from reactions conducted in the absence of a pseudo target. Indeed, the statistical "p" value was less than 0.05 for reactions in our data set that were performed using at least  $10^6$  molecules of pseudo target. This quantitatively confirmed that variability in the amount of amplicon produced in different reactions decreased when the pseudo target was present.

TABLE 2

Pseudo Target Amplification and Analyte Amplicon Synthesis						
	1AC-Bscr (copies)	BH10 RNA (copies)	Avg. net (RLU)	Amplicon (pmols)	Standard Deviation (SD)	Coefficient of Variability (CV%)
	None	60	165085	1.84	103009	62.4
	$1 \times 10^5$	60	193642	0.29	134671	69.5
	$1 \times 10^6$	60	164908	0.039	46096	28.0
	$1 \times 10^7$	60	96749	0.0029	30116	31.1
	$1 \times 10^8$	60	10199	0.0003	2475	24.3

**[0094]** Example 3 describes methods that were used to investigate whether amplification precision would also be enhanced for reactions performed in the presence of derivitized magnetic beads. In this procedure the beads were processed according to a standard specimen processing procedure which included a synthetic "target capture polynucleotide."

#### Example 3

##### Precision of Amplicon Synthesis Improved for Reactions Performed in the Presence of Processed Magnetic Beads

**[0095]** 100  $\mu$ l of a target capture reagent was combined with an equal volume of HIV seronegative plasma. The target capture reagent included 17% lithium lauryl sulfate; 190 mM succinic acid; 250 mM lithium hydroxide; 3 mM EDTA; 3 mM EGTA; 3.5 nM deoxy (-)3737 capture probe having the sequence CCCTGTTCTGCTGGAATAACTTCTGCTTCTATTTAAAAAAAAAAAAAAA (SEQ ID NO:6) and 3.5 nM 2'methoxy (-)4258 A30 capture probe having the sequence TCTGCTGTCCCTGTAATAACCCGTTAAAAAAAAAAAAAAA AA (SEQ ID NO:7). The mixture was incubated at 60°C for 20 minutes then combined with 20  $\mu$ l of bead suspension including 120  $\mu$ g of magnetic beads derivitized with oligo(dT) (Novagen; Madison WI). Reactions were then cooled to room temperature for 15 minutes to allow the hybridization of the capture probe and the immobilized oligo(dT). The beads were collected against the side of the vessel wall for 15 minutes upon positioning in a magnetic holder, and the supernatant aspirated. The beads were washed three times using 1 ml aliquots of wash reagent and used in a TMA reaction as described in Example 1, except that 100 copies of the BH10 RNA. and 0,  $10^3$ ,  $10^4$  or  $10^5$  copies of the IAC-Ascr pseudo target were used. HPA was carried out using 100 fmols of labeled AE(+)4134 probe and 200 fmols of unlabeled (+)4134 according to the procedure described above.

[0096] The results presented in Table 3 confirmed that amplification reactions that included a pseudo target advantageously yielded more uniform production of the analyte amplicon. More particularly, these results, which are based on replicates of 8 amplification reactions conducted for each level of input pseudo target, again indicated that the CV% values decreased for trials that had been performed in the presence of increasing amounts of pseudo target. Notably, levels greater than  $10^4$  copies of pseudo target per reaction gave the most statistically significant improvement in the precision of analyte amplicon synthesis.

TABLE 3

Pseudo Target Amplification and Analyte Amplicon Synthesis in the Presence of Derivitized Magnetic Beads				
IAC-Ascr (copies)	BH10 RNA (copies)	net Avg. (RLU)	Standard Deviation (SD)	Coefficient of Variability (CV%)
None	100	97105	37798	39.0
$1.0 \times 10^3$	100	152313	38630	25.4
$1.0 \times 10^4$	100	155062	67377	43.5
$1.0 \times 10^5$	100	12385	19655	15.9

[0097] The results presented in the following Example confirmed that TMA reactions that included a pseudo target, and that employed analyte polynucleotides captured on an immobilized support, exhibited enhanced precision with respect to the amount of analyte amplicon synthesized in the amplification reaction. Whereas the procedures described under Example 3 proved that the presence of a solid phase capture substrate did not adversely affect the TMA reaction, the procedures set forth below more closely parallel the manner in which diagnostic testing procedures are carried out in accordance with the invention. More particularly, the procedures used in the following Example employed captured HIV RNA as amplification templates. Variability arising from inconsistent target recovery in these procedures was normalized to permit precision of amplification to be examined independently. More specifically, the HIV RNA was first collected on magnetic beads according to a standard specimen processing protocol and then pooled and redistributed into individual tubes so that all amplification reactions could be initiated with equal amounts of HIV RNA, but with different amounts of pseudo target.

[0098] Example 4 describes the methods used to demonstrate that TMA reactions conducted using pseudo targets and analyte polynucleotide templates captured on solid substrates gave enhanced precision of amplicon production in amplification reactions.

#### Example 4

##### Pseudo Targets Enhance the Precision of Amplification Reactions that Employ Captured Analyte Polynucleotides as Templates

[0099] 100  $\mu$ l aliquots of target capture reagent and HIV virion suspension diluted in seronegative plasma containing either 0 or 200 copy equivalents of the HIV RNA/100  $\mu$ l of plasma were combined in individual reaction tubes. Target capture reagent included the following reagents at the specified concentrations: 3 mM disodium EDTA; 3 mM EGTA; 17% lithium lauryl sulfate; 190 mM succinic acid (adjusted to a final pH 5.1); 250 mM lithium hydroxide; 3.5 nM deoxy HIV(-)3837 A30 (SEQ ID NO:6); and 3.5 nM 2'methoxy HIV(-)4258 A30 (SEQ ID NO:7). Samples were incubated at 60°C for 20 minutes to liberate the HIV RNA from virions, to denature all polynucleotides and to allow the hybridization of capture probes to the target *pol* sequence. 20  $\mu$ l aliquots of oligo(dT) bead suspension containing 120  $\mu$ g of oligo (dT) derivatized beads were then added to each reaction tube. After mixing thoroughly, the samples were cooled to room temperature for 15 minutes to permit hybridization of the oligo(dA) tail of the capture probe and the bead-immobilized oligo(dT), thereby linking the analyte polynucleotide to the magnetic bead through a bridging polynucleotide. Beads and the polynucleotides immobilized thereon were isolated from plasma and free polynucleotides by placing the tubes on a magnetic rack for a period of 5 minutes, during which time the beads were collected against an inner surface of each tube. Supernatants were aspirated and the isolated beads washed three times using 1 ml aliquots of wash reagent (0.1% SDS, 10 mM HEPES (pH 7.5). 150 mM NaCl) with magnetic isolation of the beads between each step. The beads were next combined with 40  $\mu$ l of specimen buffer (1 mM EDTA, 10 mM HEPES), mixed and pooled. 40  $\mu$ l aliquots of the pooled bead suspension were then distributed to fresh reaction tubes so that all samples contained substantially identical amounts of bead-captured analyte polynucleotides. 10  $\mu$ l aliquots of pseudo target diluted in specimen buffer (1 mM EDTA, 10 mM HEPES) were distributed to appropriate tubes. Each aliquot contained either 0,  $2 \times 10^6$ ,  $2 \times 10^7$  or  $2 \times 10^8$  molecules of the IAC-Ascr or IAC Bscr pseudo target RNA. TMA amplification reactions

were performed as described above in Example 2. Analyte amplicons were detected using a modified version of the HPA procedure called, "Adduct Promoted Hydrolysis" (APH). Following the amplification reactions, each tube received a 100  $\mu$ l aliquot of acridinium labeled 2'OMe (+)4134 probe. Probes having different specific activities were used in this procedure so that amplification reactions performed using different amounts of pseudo target, whether IAC-Ascr or IAC-Bscr, would give light emission readings that fell in a linear response range for luminometry. These different specific activities were achieved by mixing labeled and unlabeled probes. Probes used to detect and quantify the analyte amplicon were as follows: reactions not receiving the pseudo target were probed with 1.0 pmol of labeled 2'OMe (+)4134 probe and 100.0 pmols of unlabeled probe; reactions that included  $10^6$ ,  $10^7$  or  $10^8$  copies of the pseudo target were probed using 1.0 pmol of labeled probe and 1.0 pmol of unlabeled probe. Reactions were incubated at 60°C for 15 minutes, mixed with 300  $\mu$ l of sodium metaarsenite-containing selection reagent, and incubated at 60°C for 20 minutes. The mixtures were cooled to room temperature and chemiluminescence was read after adding detection reagents I and II.

**[0100]** The results in Tables 4 and 5 confirmed that amplification reactions that included a pseudo target advantageously produced analyte amplicons in more uniform amounts and with less variability among the collection of sample readings. The Tables show that each reaction was primed using either 0 or 200 RNA equivalents of the HIV virion (strain HIV IIIb) as an analyte polynucleotide, and one of seven pseudo target conditions. The first condition was a negative control where the reactions were conducted in the absence of the pseudo target. The remaining conditions used either the IAC-Ascr (Table 4) or the IAC-Bscr (Table 5) pseudo target in one of three amounts. The summarized data in both Tables represents the results of 8 replicate trials conducted for each level of input pseudo target. Background emission values produced in reactions that included the pseudo target without including the model analyte polynucleotide template were subtracted to obtain the net results. The results clearly indicated that the amount of amplicon produced in the reactions decreased as the number of pseudo target molecules in the reaction increased, as expected. All amplification reactions that included a pseudo target resulted in the production of more uniform amounts of analyte amplicon. More particularly, the CV% values were lower among all data sets derived from reactions that included pseudo targets when compared to the negative control that was conducted in the absence of a pseudo target. These results supported the conclusion that precision in the amount of analyte amplicon produced in an amplification reaction can be improved by including a pseudo target in the reaction. The fact that two different pseudo targets gave similarly good results showed that the improved precision did not depend of the particular sequence of the pseudo target. These results further showed how precision in the amount of analyte amplicon produced in an amplification reaction can be improved by including pseudo targets in reactions that employed analyte polynucleotides captured by a solid support, such as a magnetic bead, as templates for the amplification reaction.

TABLE 4

Different Pseudo Targets Improve the Precision of Analyte Amplicon Production					
IAC-Ascr Pseudo Target (copies)	HIV Virion (copies)	Avg. net (RLU)	Amplicon (pmol)	Standard Deviation (SD)	Coefficient of Variability (CV%)
None	200	69858	0.95	57195	81.9
$2 \times 10^6$	200	166824	0.03	62799	37.6
$2 \times 10^7$	200	26733	0.0041	13616	50.9
$2 \times 10^8$	200	3043	0.0005	585	19.2

TABLE 5

Improved Precision of Analyte Amplicon Production Using Different Pseudo Targets					
IAC-Bscr Pseudo Target (copies)	HIV Virion (copies)	Avg. net (RLU)	Amplicon (pmol)	Standard Deviation (SD)	Coefficient of Variability (CV%)
None	200	69858	0.95	57195	81.9
$2 \times 10^6$	200	109125	0.0166	37519	34.4
$2 \times 10^7$	200	14904	0.0023	10669	71.6
$2 \times 10^8$	200	1492	0.0002	697	46.8

[0101] Yet another advantage of conducting amplification reactions in the presence of a pseudo target relates to normalizing the amount of amplicon produced when the input analyte polynucleotide is recovered from a biological sample at less than quantitative yield. The basis of this advantage, which is illustrated in Figure 5, has been addressed above. The following Example was used to model situations wherein the recovery of analyte polynucleotides from a biological sample differed substantially. More particularly, conditions examined ranged from the equivalent of from 100% to 25% recovery. Such differences in the efficiency of analyte polynucleotide recovery could arise for reasons including variable recovery from phenol extraction procedures, ethanol precipitation procedures, difficult specimen collection or extraction conditions or even a laboratory spill leading to sample loss. In each case, the amount of analyte polynucleotide recovered would be less than a quantitative recovery.

[0102] As described below, the variable efficiency of analyte polynucleotide recovery was modeled by performing amplification reactions under three different conditions. Under the first condition, reactions were performed using three different amounts of input analyte polynucleotide without pseudo target. The second condition involved reactions performed using the same three different amounts of input analyte polynucleotide and a constant amount of pseudo target. Finally, the third reaction condition employed the same three different amounts of input analyte polynucleotide, where the ratio of the amounts of analyte polynucleotide and pseudo target were constant. It will be apparent that this third condition represents a case which would result when the pseudo target was added to a biological sample containing analyte polynucleotide at a time before nucleic acids were isolated from the sample. Under this circumstance, loss of a portion of the sample during processing steps would result in identical percentage losses of both analyte polynucleotide and pseudo target, yet the ratio of the two species would remain fixed. As will be apparent from the results that follow, amplification reactions that included a constant ratio of pseudo target and analyte polynucleotide advantageously gave improved synthesis of analyte amplicons. Thus, even reactions having a limited number of input analyte polynucleotides behaved as though the starting number of templates was larger.

[0103] The results obtained in the Example which follows provided the basis for the improved method of biological specimen processing that includes adding pseudo targets to the specimen before nucleic acids are isolated. One method of normalizing the level of analyte amplicon produced in an amplification reaction involves first adding the pseudo target to a biological specimen, then isolating polynucleotides from the specimen and thereafter using the polynucleotides isolated in this fashion to conduct the amplification reactions.

[0104] Example 5 describes the methods that were used to represent amplification reactions that were initiated using variable amounts of analyte polynucleotide. More particularly, the reactions were performed so that the amounts of analyte polynucleotide represented "100%, " "50%" and "25%" values.

### Example 5

#### Normalizing Amplicon Synthesis in Amplification Reactions Primed with Variable Amounts of Analyte Polynucleotide

[0105] Amplification reactions were prepared according to the method of Example 1 with the following changes. First, replicates of 10 reactions for each condition were prepared instead of replicates of eight. Second, primer amounts used in the reactions were reduced to 5 pmols each, instead of 10 pmols each. Third, 20% polyvinylpyrrolidone was substituted by 10% trehalose. Fourth, the amounts of analyte polynucleotide and pseudo target were as presented in Table 6. In our procedures, the polynucleotide mixtures presented in this Table were first combined, then mixed with other reagents in the reaction mixture, and finally mixed with the two polymerase enzymes to initiate the TMA reaction.

TABLE 6

Mixtures of Analyte Polynucleotide and Pseudo Target			
Condition	BH 10 RNA (copies)	IAC-Ascr (copies)	
No Pseudo Target	500	0	
	1000	0	
	2000	0	
Constant Pseudo Target	500	$6 \times 10^6$	
	1000	$6 \times 10^6$	
	2000	$6 \times 10^6$	

TABLE 6 (continued)

Mixtures of Analyte Polynucleotide and Pseudo Target			
Condition	BH 10 RNA (copies)	IAC-Ascr (copies)	
Constant Ratio of Pseudo Target and Analyte Polynucleotide	500	1.5 x 10 <sup>6</sup>	
	1000	3.0 x 10 <sup>6</sup>	
	2000	6.0 x 10 <sup>6</sup>	

At the conclusion of the amplification reactions, all reaction mixtures were probed according to the APH protocol described above in Example 4 to detect and quantitate analyte amplicons. AE labeled HIV (+)4134b probe having the sequence CCACAATTAAAAGAAAAGGG (SEQ ID NO:8) of different specific activities was used in this procedure so that the amplification reactions performed using different amounts of pseudo target would give light emission readings that fell within a linear response range for luminometry. Again, these different specific activities were achieved by mixing different amounts of labeled and unlabeled probes. Probes used to detect and quantify the analyte amplicon were as follows: reactions not receiving the pseudo target were probed using 1.3 pmols of labeled probe and 400 pmols of unlabeled probe; reactions that included 1.5 x 10<sup>6</sup>, 3 x 10<sup>6</sup> or 6 x 10<sup>6</sup> copies of pseudo target were probed using 1.3 pmols of labeled and 8.7 pmols of unlabeled probe.

**[0106]** The quantitative results presented in Tables 7 - 9 and in Figure 6 clearly indicated that reactions in which the ratio of pseudo target to analyte polynucleotide was held constant yielded substantially smaller differences in the amounts of analyte amplicon synthesized from variable amounts of input analyte polynucleotide. All results were based on replicates of 10 trials conducted for each level of input analyte polynucleotide template. In Figure 6, 100% of input analyte polynucleotide was represented by 2,000 copies of BH10 RNA. In the absence of pseudo target the slope of the line representing the amount of analyte amplicon produced at decreasing levels of input analyte polynucleotide, declined sharply as the number of these template decreased from 2,000 to 500. A similar result was obtained in the trials containing a constant level of pseudo target. Thus, procedures that involved merely adding pseudo target to a sample having a low level of input analyte polynucleotides had substantially no effect on increasing the amount of analyte amplicon that was synthesized. However, the amplification reactions that were carried out using a constant molar ratio of pseudo target to analyte polynucleotide yielded smaller differences in the amounts of analyte amplicon synthesized from variable amounts of input analyte polynucleotide. For example, the results shown in the Figure indicate that at 500 copies of input BH10 RNA, the yield of analyte amplicons (measured in RLU) was about 68% of the value obtained using 2000 copies of the template, while the corresponding result obtained in the absence of pseudo target or when pseudo target was held constant only was about 22%. Conducting amplification reactions using a constant ratio of pseudo target and analyte polynucleotide tended to normalize the amount of analyte amplicon synthesized in the amplification reaction. Also, the ratio may be varied somewhat depending on input level and desired accuracy of quantitation. Significantly, substantially similar results were obtained when the reactions were conducted in the presence of magnetic beads and a capture reagent, as described under Examples 3 and 4. Moreover, the data presented in Tables 7 - 9 show that precision of amplification reactions was improved by including a pseudo target in the amplification reaction.

TABLE 7

TMA Reactions Conducted in the Absence of a Pseudo Target				
BH10 RNA (copies)	net Avg (RLU)	% of 2000	Standard Deviation (SD)	Coefficient of Variability (CV%)
None	0	0	N/A	N/A
500	35279	22.4	10033	28.4
1000	70202	44.7	36070	51.4
2000	157176	100	26792	17.0

TABLE 8

TMA Reactions Having Constant Pseudo Target Levels				
BH10 RNA (copies)	net Avg (RLU)	% of 2000	Standard Deviation (SD)	Coefficient of Variability (CV%)
None	0	0	N/A	N/A

TABLE 8 (continued)

TMA Reactions Having Constant Pseudo Target Levels				
BH10 RNA (copies)	net Avg (RLU)	% of 2000	Standard Deviation (SD)	Coefficient of Variability (CV%)
500	96434	22.2	23442	24.3
1000	224493	51.6	49903	22.2
2000	434899	100	30382	7.0

10

TABLE 9

TMA Reactions Having a Constant Ratio of Analyte Polynucleotide and Pseudo Target				
BH10 RNA (copies)	net Avg (RLU)	% of 2000	Standard Deviation (SD)	Coefficient of Variability (CV%)
None	0	0	N/A	N/A
500	294660	67.8	43197	14.7
1000	340594	78.3	72128	21.2
2000	434899	100	30382	7.0

15

20

25

30

35

40

**[0107]** The following Example describes experiments that were carried out to show how incorporating a pseudo target into an amplification reaction can be used to control the amount of amplicon produced in the reaction. As indicated above, reducing the amount of amplicon produced in a reaction advantageously: (1) reduces the likelihood of positive carry-over contamination; (2) allows for more efficient use of labeled probes; and (3) may be used to "tune" signal strength to fall within a linear range for detection apparatus such as a luminometer. With respect to this second point, with reduced numbers of product amplicon produced in a reaction it becomes possible to employ very high specific activity probes in quantities sufficient to provide probe excess. Those having an ordinary level of skill in the art will appreciate that the specific activity of a hybridization probe refers to the amount of detectable label per probe molecule. High specific activity probes are useful for detecting minute quantities of complementary polynucleotides. However, if the probe is expensive to prepare, or is labeled with a radioactive label that requires special handling and disposal precautions, it may not be desirable to use high specific activity probes in large quantities that would be needed to carry out quantitative hybridizations using probe excess conditions. Thus, reducing the amount of analyte amplicon produced in an amplification reaction advantageously can facilitate efficient use of probes that are employed for detecting the amplicons.

**[0108]** Example 6 describes methods that were used to demonstrate how pseudo targets can be used to control the amount of analyte amplicon produced in an amplification reaction.

#### Example 6

##### Employing Pseudo Targets to Control the Production of Analyte Amplicons

45

50

55

**[0109]** 100  $\mu$ l of target capture reagent (17% lithium lauryl sulfate; 190 mM succinic acid; 250 mM lithium hydroxide; 3 mM EDTA; 3 mM EGTA; 3.5 nM 2' methoxy (-)3837 A30 capture probe (SEQ ID NO:6) and 3.5 nM 2' methoxy (-)4258 A30 capture probe (SEQ ID NO:7) was combined with 100  $\mu$ l of HIV virion diluted in HIV seronegative plasma. Samples contained either no HIV RNA; 200; 2,000; 20,000; 200,000 or 2,000,000 RNA equivalents/ml of plasma. Mixtures were incubated at 60°C for 20 minutes to allow hybridization of the capture probe with *pol* gene sequences present in target polynucleotides, and then combined with 20  $\mu$ l of oligo(dT) bead suspension (120  $\mu$ g of oligo(dT) beads/20  $\mu$ l). After mixing thoroughly, samples were cooled to room temperature over a period of 15 minutes to allow hybridization of the oligo(dA) of the capture probe and the bead-immobilized oligo(dT), thereby linking the *pol* gene sequence and the magnetic bead. Beads were collected against the sides of the tubes using a magnetic rack and the supernatants aspirated. Beads were washed three times using 1 ml volumes of wash reagent (0.1% SDS; 10 mM HEPES (pH 7.5); 150 mM NaCl). 50  $\mu$ l aliquots of specimen buffer (10 mM HEPES; 1 mM EDTA) were added to tubes that did not receive any pseudo target. 50  $\mu$ l aliquots of pseudo target diluted in specimen buffer were added to tubes that did receive the pseudo target. After mixing, each sample received a 25  $\mu$ l aliquot of amplification reagent containing: 5 pmols of a T7A(-)4190 primer; 5 pmols of the (+)4108 primer; 160 mM Tris buffer (pH 7.5); 16 mM each of ATP, CTP, GTP and UTP; 4 mM each of dATP, dCTP, dGTP and dTTP; 100 mM  $MgCl_2$ ; 70 mM KCl; 20% glycerol; 0.6 mM zinc

acetate and 10% trehalose. Samples were overlaid with 200  $\mu$ l of mineral oil and then incubated at 42°C for 10 minutes. Amplification reactions were initiated by adding 25  $\mu$ l aliquots of enzyme reagent containing 2000 GP units of MMLV reverse transcriptase; 2000 GP units of T7 RNA polymerase; 140 mM Tris buffer (pH 8.0); 100 mM N-acetyl-cysteine as a reducing agent; 20% glycerol; 70 mM KCl; 80 mM trehalose; 8 mM HEPES; 1.04 mM EDTA; 10% TRITON X-102 and 0.01 % phenol red. All reactants were mixed and allowed to incubate at 42°C for 1 hour.

**[0110]** At the conclusion of the reaction period, analyte amplicons were quantified using the above-described APH procedure. A 100  $\mu$ l aliquot of a solution of acridinium labeled probe AE(+)-4 134b was added to each sample. Samples corresponding to reactions that included the pseudo target received 1.3 pmols of labeled probe and 38.7 pmols of unlabeled probe, while samples corresponding to reactions that did not include the pseudo target received 1.3 pmols of labeled probe and 400 pmols of unlabeled probe. Mixtures were incubated at 60°C for 15 minutes and then combined and mixed with 300  $\mu$ l of APH selection reagent containing sodium metaarsenite. Reaction mixtures were incubated at 60°C for 20 minutes and then cooled to room temperature. Chemiluminescence was read following addition of detection reagents I and II.

**[0111]** Notably, preliminary experiments were carried out in which routine APH procedures were conducted using a range of specific activities to identify conditions that would give results falling within the linear detection range of the luminometer used in our experiments. Those having ordinary skill in the art readily will appreciate that many sorts of detection apparatus, whether a luminometer or an X-ray film, have a range within which the intensity of a signal and the amount of material that produced the signal are linearly or exponentially related. Above that range, the correspondence does not hold. Thus, determining such linear ranges is a matter of routine experimentation for those having ordinary skill in the art.

**[0112]** The probe mixtures employed for detecting analyte amplicons in our procedure were: 401.3 pmols of probe consisting of 1.3 pmols labeled probe and 400 pmols of unlabeled probe for the reaction conducted in the absence of a pseudo target; and 40 pmols of probe consisting of 1.3 pmols labeled probe and 38.7 pmols of unlabeled probe for the reaction that included the pseudo target. In order to normalize the results of the assay, light intensity readings (measured in RLU) were converted into pmols of amplicon in the hybridization step by multiplying the average net RLU values by a conversion factor. This conversion factor was established by hybridizing, in parallel reactions, known amounts of target polynucleotide and excess amounts of labeled probe and then determining the light output generated by the known amount of target. This allowed correlation of light output and the amount of amplicon hybridized to the probe.

**[0113]** The results presented in Tables 10 and 11 and in Figure 7 indicated that the presence of a pseudo target in an amplification reaction did not compromise the correlation between the amount of input analyte polynucleotide and the amount of analyte amplicon produced in amplification reactions. All results were based on replicates of 5 trials conducted for each level of input HIV IIb RNA used in the procedure. The log plot shown in Figure 7 clearly indicates a strong relationship between the amount of HIV IIb RNA equivalents input into a reaction and the amount of analyte amplicon produced. Clearly, this same strong linear relationship prevailed when the amplification reactions additionally included the pseudo target. The downward shift observed for the line representing analyte amplicons produced in reactions that included pseudo targets indicates that fewer molecules were produced when compared with reactions that did not include pseudo targets. For example, the results shown in Table 10 indicate that approximately 520 pmols of analyte amplicon were produced in the reaction that included 200,000 HIV RNA equivalents, and that this number was reduced by about ten fold when the pseudo target was included in the reaction. Thus, the number of analyte amplicons produced in the amplification reaction was reduced by including a pseudo target in the reaction.

TABLE 10

Controlling Analyte Amplicon Production Using Pseudo Targets			
HIV IIb RNA equivalents/reaction	No Pseudo Target		
	Avg net (RLU)	Amplicon (pmols)	Standard Deviation (SD)
None	0	0	N/A
20	47878	2.5	55529
200	137756	7.2	143360
2000	794621	41.7	174616
20,000	4762815	250	609171
200,000	9908427	520	639895

TABLE 11

Controlling Analyte Amplicon Production Using Pseudo Targets			
HIV IIIb RNA equivalents/reaction	2 x 10 <sup>6</sup> Pseudo Target Molecules (IAC-Ascr)		
	Avg net (RLU)	Amplicon (pmols)	Standard Deviation (SD)
None	0	0	N/A
20	1623	0.01	2224
200	10473	0.067	8000
2000	84435	0.54	8449
20,000	802975	5.1	189079
200,000	8083585	51.5	1567615

Qualitative Format Assays

[0114] Although the foregoing description relates to quantitative assays, other useful procedures that employ pseudo targets in amplification reactions relate to qualitative assays that provide information about the presence or absence of an analyte polynucleotide in a test sample. Qualitative tests can also be used for indicating whether or not an analyte polynucleotide in a test sample is present at a level falling within a specified range. These assays could, for instance, be used to monitor a patient's response to drug therapy. For example, a patient infected with a blood borne virus may experience a change in the plasma titer following therapeutic drug treatment. A physician can monitor whether the patient's virus titer increases or decreases with respect to a particular threshold value using a qualitative assay that incorporates pseudo target amplification. It is to be understood that a qualitative testing format involves only detection of a signal and so would not necessarily require quantitative measurement of the signal or the production or use of a standard curve by an end-user of a diagnostic assay.

[0115] In certain preferred embodiments of the invention qualitative assays are performed to indicate whether a biological sample contains an analyte polynucleotide. In other preferred embodiments of the invention assays that produce only qualitative results (i.e., a result is either positive or negative) but can provide semi-quantitative information about an analyte polynucleotide in a sample.

[0116] Qualitative assays that co-amplify analyte polynucleotides and pseudo targets are especially versatile when combined with detection protocols having specified thresholds of detection. These thresholds can be manipulated by adjusting the specific activity of a hybridization probe, or by calibrating the detection device to specify a negative result below a certain numerical value or a positive result above a certain value. For example, a luminometer can be set to indicate a positive result for RLU values greater than a certain threshold level. Alternatively, the amount of pseudo target included in the amplification reaction can be increased or decreased so that certain levels of analyte amplicon produce detectable signals that are either above or below the limit of detection for a particular device. Thus, the amount of pseudo target input into an amplification reaction for a diagnostic assay can be adjusted or "tuned" through routine experimentation so that a detection signal falling within a desired range is produced.

[0117] When an analyte polynucleotide and a pseudo target are co-amplified according to the above-described procedures, the amount of analyte amplicon synthesized in the reaction will naturally be related to the amount of analyte polynucleotide that was input into the reaction. Since the magnitude of a hybridization signal can be tuned by one of the procedures described above, since amplification reactions that incorporate pseudo targets advantageously are characterized by enhanced precision, and since it is possible to tune a diagnostic reaction so that a given level of input analyte polynucleotide produces a hybridization signal that is above or below a detection threshold for a testing instrument it is possible to produce qualitative assays that also provide quantitative information.

[0118] The following Example illustrates how semi-quantitative information about the amount of analyte polynucleotide in a test sample can be obtained using a qualitative assay that provides only positive or negative results. For illustrative purposes, the HIV polynucleotide serves as the analyte polynucleotide and the indicated titer range is based on results presented in the previous Example. Of course, other analyte polynucleotides and different threshold ranges also can be employed in this qualitative testing format. Also, detection by luminometry can be substituted by fluorescence or other optical or electro-chemical detection methods. Pseudo target can be combined with a biological sample and nucleic acids isolated thereafter, or simply combined with pre-isolated analyte polynucleotide prior to the co-amplification step. In this Example the detection system includes a detection device (luminometer), a labeled hybridization probe that can be detected by the detection device. Based on the preceding description it should be clear that the specific activity of the labeled probe and the amount of pseudo target included in the co-amplifying step are both

variables that can be manipulated to control the threshold of detection in the detection system.

[0119] Example 7 describes how amplification reactions that include pseudo targets can be used in a qualitative assay format to derive semi-quantitative information about pre-amplification amounts of analyte polynucleotide.

5 **Example 7**

Qualitative Assay Formats

[0120] A physician treating a patient infected with HIV desires to monitor the effectiveness of a drug treatment protocol. The physician specifically desires to know when the patient's plasma titer is reduced from a high starting level to a lower level that corresponds to below about 200 RNA equivalents in 100  $\mu$ l of plasma.

[0121] First and second plasma samples are obtained from the patient at times before and after commencing drug therapy. Samples are prepared and used for amplification reactions essentially as described under Example 6. Individual 100  $\mu$ l aliquots of the plasma samples are mixed with 100  $\mu$ l aliquots of target capture reagent and the mixtures incubated, combined with oligo(dT) bead suspension, mixed again and then cooled to room temperature. Beads are collected, washed and then combined with 50  $\mu$ l aliquots containing  $2 \times 10^6$  copies of pseudo target diluted in specimen buffer. After mixing, each sample receives a 25  $\mu$ l aliquot of amplification reagent containing primers and nucleotide reactants. Samples are overlaid with 200  $\mu$ l of mineral oil and then incubated at 42°C for 10 minutes. Amplification reactions are initiated by adding 25  $\mu$ l aliquots of enzyme reagent containing 2000 GP units of MMLV reverse transcriptase and 2000 GP units of T7 RNA polymerase in a buffered solution. All reactants are mixed and allowed to incubate at 42°C for 1 hour. Amplified samples are then subjected to an APH detection procedure. A solution of acridinium labeled probe AE(+)4134b is added to each sample. Each sample receives 1.3 pmols of labeled probe and 38.7 pmols of unlabeled probe, where each probe is specific for authentic HIV amplicons but not pseudo target amplicons. These amounts of probe represent saturating hybridization amounts so that analyte amplicons will be quantitatively detected. Mixtures are incubated at 60°C for 15 minutes and then combined and mixed with 300  $\mu$ l of APH selection reagent containing sodium metaarsenite. Reaction mixtures are incubated at 60°C for 20 minutes and then cooled to room temperature. Chemiluminescence is read following addition of detection reagents I and II using a luminometer programmed to indicate a positive result for RLU values of 10,000 or greater and a negative result for RLU values less than 10,000. The pre-treatment plasma sample gave a positive result, thereby indicating a level of at least about 200 RNA equivalents. Conversely, the post-treatment plasma sample gave a negative result, thereby indicating a level of less than 200 RNA equivalents in the 100  $\mu$ l sample. The physician judges that the drug treatment is effective at reducing viral load.

[0122] This invention has been described with reference to a number of specific examples and embodiments thereof. Of course, a number of different embodiments of the present invention will suggest themselves to those having ordinary skill in the art upon review of the foregoing detailed description. Thus, the true scope of the present invention is to be determined upon reference to the appended claims.

SEQUENCE LISTING

40 [0123]

<110> GEN-PROBE INCORPORATED  
 <120> POLYNUCLEOTIDE AMPLIFICATION METHOD  
 45 <130> GP104-PCT  
 <160> 9  
 50 <170> FastSEQ for Windows Version 3.0  
 <210> 1  
 <211> 55  
 <212> DNA  
 55 <213> Artificial Sequence  
 <220>  
 <223> Primer T7A(-)4190

&lt;400&gt; 1

aatttaatac gactcactat agggagagtt tttatgtctg ttgttattat gtcta

55

5 &lt;210&gt; 2

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

10 &lt;220&gt;

&lt;223&gt; Primer (+)4108

&lt;400&gt; 2

15

acagcagtac aaatggcag

19

&lt;210&gt; 3

&lt;211&gt; 8933

20 &lt;212&gt; RNA

&lt;213&gt; Human Immunodeficiency Virus

&lt;220&gt;

&lt;221&gt; source

25 &lt;222&gt; (1)...(8933)

&lt;223&gt; Sequence of transcripts produced from the BH10 plasmid.

&lt;400&gt; 3

30

gagcucucuc	gacgcaggac	ucggcuugcu	gaagcgcgca	cggcaagagg	cgagggggcg	60
cgacugguga	guacgc当地	aaauuuugacu	agcggaggcu	agaaggagag	agauggggugc	120
gagagcguca	guauuaagcg	ggggagaaauu	agaucgaugg	aaaaaaauuc	gguuaaggcc	180
agggggaaaag	aaaaaaauaua	aaauaaaaaca	uaauaguauugg	gcaagcaggg	agcuagaacg	240
auucgcaguu	aauccuggcc	uguuuagaaaac	aucagaaggc	uguagacaaa	uacugggaca	300
gcuacaacca	ucccuucaga	caggaucaga	agaacuuaga	ucauuauaua	auacaguagc	360
aacccucuau	ugugugcauc	aaaggauaga	gauaaaaagac	accaaggaag	cuuuagacaa	420
gauagagggaa	gagcaaaaca	aaaguaagaa	aaaagcacag	caagcagcag	cugacacagg	480
acacagcagu	caggucagcc	aaaauuaccc	uaauagugcag	aacaucagg	ggcaaauuggu	540
acaucaggcc	auaucaccua	gaacuuuuuaa	ugcaugggua	aaaguaguag	aagagaaggc	600
uuucagccca	gaaguaauac	ccauguuuuc	agcauuauca	gaaggagcc	ccccacaaga	660
uuuuaacacc	augcaaaca	cagugggggg	acauuaagca	gccaugccaa	uguuaaaaga	720
40 gaccaucaau	gaggaagcug	cagaauggga	uagaguacau	ccagugcaug	cagggccuau	780
ugcaccaggc	cagaugagag	aaccaagggg	aagugacaua	gcaggaacua	cuaguacccu	840
ucaggaacaa	auaggaugga	ugacaaaauaa	uccaccuauc	ccaguaggag	aaauuuauaa	900
aagauggaua	auccugggau	uaaaauaaaa	aguaagaaug	uuuagccua	ccagcauucu	960
ggacauaaga	caaggaccaa	aagaaccuuu	uagagacauu	guagaccgg	ucuauaaaac	1020
ucuaagagcc	gagcaagcuu	cacaggaggu	aaaaaaauugg	augacagaaa	ccuuguuggu	1080
caaaaaugcg	aaccaggauu	guaagacuau	uuuaaaaagca	uugggaccag	cggcuacacu	1140

45

50

55

5	agaagaaaug augacagcau gucagggagu aggaggaccc ggc当地 aaggaguuuu 1200 ggcugaagca augagccaag uaacaaaauac agcuaccaua augauggcaga gagggcaauuu 1260 uaggaaccaa agaaaagauugg uuaaguguu caauuguggc aaagaagggc acacagccag 1320 aaaauugcagg gcccccuuagaaaagggc uuggaaaugu gaaaaggaaag gacacaaaau 1380 gaaagauugu acugagagac aggcuaauuu uuuagggaag aucuggccuu ccuacaagg 1440 aaggccaggg auuuuucuuc agagcagacc agagccaaaca gccccaccau uucuucagag 1500 cagaccagag ccaacagcccc caccagaaga gacuucagg ucugggguag agacaacaac 1560 ucccccucag aagcaggagc cgauagacaa ggaacuguau ccuuuacuu cccucagcauc 1620 acucuuuggc aacgaccccu cgucacaaua aagauagggg ggcaacauaaa ggaagcucua 1680 uuagauacag ggc当地 gacuauua gaagaaauga guuugccagg aagauggaaa 1740 ccaaaaaugg uagggggauu uggaggguuuu aucaaaguua gacaguaua ucagauacuc 1800 auagaaaauu guggacauaa agcuauaggu acaguauuag uaggaccuac accugucaac 1860 auuuuuggaa gaaaucuguu gacuagguu gguugcacuu uuuuuuuccu cauuagccu 1920 auugagacu uacuagguu uuuuaggc ggauggaag gcccccaauu uaaacaaugg 1980 ccauugacag aaaaaaaaauu aaaagcaua guagaaauuu guacagaaaa gaaaaggaa 2040 ggggaaaauuu caaaaauugg gccugagaaau ccuacauaua cuccaguauu ugccauaaag 2100 aaaaaaagaca guacuauua gagaauauua guagauuuu gagaacuuua uaagagaacu 2160 caagacuucu gggaauguuca auuaggaaua ccacaucccg caggguuuuaa aaagaaaaaa 2220 ucaguaacag uacuggaauu gggugugca uuuuuuucag uucccuuaga ugaagacuuc 2280 aggaaguaua cugcauuuac cauaccuagu auuuacaaug agacaccagg gauuagauau 2340 caguacaaug ugcuuccaca gggauuggaa ggaucaccag caauauucca aaguagcaug 2400 acaaaaauu uagagccuuu uaaaaacaa aaucaggaca uaguauucua ucaauacau 2460 gaugauuugg auugaggauc ugacuauua auaggcagc auagaacaaa aauagaggag 2520 cugagacaac aucuguugag guggggacuu accacaccag aaaaaaaaac ucaaaaaagaa 2580 cccuuauucc uuuugggg uuaugaacuc cauccugaua auggacagu acagccuaua 2640 gugcugccag aaaaagacag cuggacuguc aaugacauac agaaguuagu gggggaaauug 2700 aaauugggcau gucagauuuu cccagggauu aaaguaaggc auuuaugua acuccuuaga 2760 ggaacccaaag cacuacaga aguaauacca cuaacagaag aagcagacu agaacuggca 2820 gaaaacagag agauucuaaa agaaccagua cauggagugu auuaugaccc aucaaaagac 2880 uuuuuagcag aaaaacagaa gcaggggcau ggccaaugga caauuacaaau uuuucaagag 2940 ccauuuuaaa aucugaaaaac aggaaaaauu gcaagaaua ggggugccca cacuauugau 3000 guuuuacaaau uacagaggc agugcaaaaa auaaccacag aagcagacu agaacuggca 3060 aagacuccua auuuuuacu acccauacaa aaggaaaacau gggaaacacu gggaaacacu guggacagag 3120 uuuuggcag ccacuuggau uccugagugg gaguuuguu auacccuccc uuuuagugaaa 3180 uuuugguacc aguuagagaa agaacccaua guaggagcag aaaccuuuca uguauuggg 3240 gcagcuaaca gggagacuua auuagggaaa gcaggauaug uacuaacaa aggaagacaa 3300 aaggugucc cccuaacua cacaacaaau cagaaaacug aguuacaagc auuuuuacua 3360 gcuuuggcagg auucaggauu agaaguaaac auaguaacag acucacaaua ugcauuagga 3420 aucauuuacu cacaaccaga uaaaagugaa ucagaguau ucaauuacaaau aauagaggcag 3480 uuuuuacaaa aggaaaaaggc cuacuggca uggguaccag cacacaaagg aauuugggagga 3540 aaugaacaaag uagauuuuau agucagugc ggaauacagg aauuacuuau uuuuagugga 3600 auagauuagg cccaaagaua acauagaaaa uaucacaguu auuggagagc auggcuagu 3660 gauuuuuaacc ugccacuug aguagcaaaa gaaaauaguag ccagcuguga uuuuugucag 3720 cuuuuaggag aaggccauca uggacaagu gacuguaguc caggaauau gcaacuagau 3780 uguacacauu uagaaggaaa aguuuuccug guagcaguuc auguagccag ugauauaua 3840 gaagcagaag uuauucccgc agaaacaggc cagggaaacag cauuuuuccu uuuuacuuua 3900 gcaggaagau ggccaguaaa aacaauacau acagacaaug gcagcaauu caccagugcu 3960 acgguuuagg ccgcugug guggggcggg aucaagcagg auuuugggau ucccuuacau 4020 ccccaaaguc aaggaguugu agaaacuau aauuagaaaa uuuuacaaaau uuuuaggacag 4080 guuaggagac aggcugacu ucuuauagca gcauacaaa ugugcuauu cauccacau 4140 uuuuuacaaa aaggggggau ugaaaaaggc agugcagggg aaaaauagu agacauaua 4200 gcaacagaca uacaaacaua aguuuacaa aaacaaauu caaaaauuca auuuuuucgg 4260 guuuuacuac gggcagcagc aauuccacu uggaaaggac cagcaacgcu ccucuggaaa 4320 ggugaaagggg caguauuuu acaagauuu agugacauaa aaguagugcc aagaagaaaa 4380 gcaaaagauca uuagggauua ugaaaacag auggcaggug augauugugu ggcaaguaga 4440 caggauuggg auuagaacau gggaaaguuu aguaaaacac cauauuguau uuuuaggggaa 4500 agcuagggg ugguuuuaaua gacauacua ugaaaggccu cauccaagaa uaaguucaga 4560 aguacacauu ccacuagggg augcuauuu gguauuuaca acauauugg gugcugcuauc 4620 aggagaaaga gacuggcavu uggugcagg agucuccaua gaauggagga aaaagagagaua 4680 uagcacacaa guagacccug aacuacgaga ccaacauuu caucuguau acuuuugacug 4740 uuuuuucagac ucugcuaua gaaaaggccu auuaggacac auaguuagu cuaggugug 4800 auauuacacaa ggacauuaaca agguaggauc ucuacauuu acuaggcucu cagcaauuaau 4860 aacacaaaaa aagauuaaggc caccuuugcc uaguguuacg aacuacgacag aggauuagaug 4920 gaacaagccc cagaagacca agggccacag agggagccac acaauuaug gacacuagag 4980 cuuuuagagg agcuuaagaa ugaagcuguu agacauuuuc cuaggauuu gcuuccauggc 5040 uuagggcaac auauuacuaua aacuuuuggg gauacuuggg caggagugga agccauuaaua 5100
30	
35	
40	
45	
50	
55	

5	agaauuucugc aacaacugcu guuuuauc cau uucagaauu gggugugc gac auagcagaau aggcguuacu cgacagagga gagcaagaaa uggagccagu agauccuaga cuagagccu ggaagcaucc aggaagucag ccuaaaaacug cuuguaccau uugcuauug uaaaagugu gcuuiucuug ccaaguuuug uucauaaca aagccuagg caucuccuau ggcaggaaga agcggagaca ggcgacgaaga cccuccucaag gcagucagac ucaucaagu uucucauca agcaguaagu aguacaugua augcaaccua uacaaaugc aauaguagca uuaguaguag caauauauau agcaauaguu guguggucca uaguaucau agaaauuagg aaaaauuuua gacaaagaaa aauagacagg uuaauugaua gacuaauaga aagagcagaa gacaguggca augagaguga aggagaaaaua ucagcacuug uggagauugg guggagau gggcaccaug cuccuuggga uguugaugau cuguagugc acagaaaaau ugugggucac agucuaauuau gggguaccug uguggaagag agcaaccacc acucuauuu gugcaucaga ugcuaaagca uaugauacag agguacauaa uguuuggggc acacaugccu gugucaccac agaccccaac ccacaagaag uaguauugg uaaugugaca gaaaauuuua acauguggaa aaaaugacaug guagaacaga ugcaugagga uavaauacagu uuaugggauc aaagccuaaa gcaugugua aaaauuaccc cacucugugu uaguauuaag ugcacugau ugaagaauga uacuaauacc aauguagua gccccgagaau gauaugggag aaaggagaga uaaaaaacug cucuucaau aucagcacaa gcauaagagg uaaggugcag aaagaauaugg cauuuuuuua uaaacuugau auuaauacca uagauuauga uacuaccagc uauacguuga caaguugua caccucaguc auvacacagg ccuguccaaa gguauccuuu gagccaaauuc ccauacauua uuguggcccg gcugguuuug cgawcuuuaau aagacguu auggaacagg accauguaca aaugucagca caguacaaug uacacauuga auuaggccag uguaucaac ucaacugcug uuaauuggca gucuggcaga agaagaggua guauuugau cugccauuuu cacagacaau gcuaaaaaaccu uuaauuguaca gcugaaacca ucuguagaaa uuaauugua aagacccaaac aacaauacaa gaaaaaguau ccguauccag agaggaccag ggagagcauu uguuacaaua gaaaaauuag gaaaaauugag acaagcacau uguuacaua guagagcaaa auggaauaac acuuuuaaac agauagauag caauuaaga gaacaaauuug gaaauuauaa aacaauuauc uuaagcagu ccucaggagg ggaccaggaa auuguaacgc acaguuuuua uuguggaggg gaauuuuucu acuguaauuc aacacaacug uuaauuagu uuggguuuua uaguacuugg aguacuaaag ggucaauuaa cacugaagga agugacacaa ucacccuccc augcagaaua aaacaaauua uaaacauug gcaggagga gaaaaagcaa uguauugccc ucccaucagu ggacaaauua uaaacauug gcaggagga gaaaaagcaa uguauugccc ucccaucagu agcaacaaug agucggagau cuucagacu ggaggaggaa auauugaggaa caauuggaga agugaauuuu auuaauuauaa aguaguaaaa auugaaccu uaggaguagc accccaccaag gcaaagagaa gaguggugca gagagaaaaa agagcagugg gaaauaggagc uuguuuccu ggguucuugg gagcagcagg aagcacaua ggcgcagcgu caaugacgcu gacgguacag gccagacaaau uauugucugg uauagugcag cagcagaaca auuugcugag ggcuaauugag gcgcaacagc aucuguugca acucacaguc uggggcauca agcagcucca ggcaagaauc cuggcugugg aaagauaccu aaaggauca cagcuccugg gauuugggg uugcucugga aaacucauu gcaccacugc ugugccuugg aaugcuau uguauuggg uugcucugga cagauuugga auaacaugac cugguuggg uggaacagag aauuaacaa uacacaac uuaauacacu ccuuaauuuga agauuugccaa aaccagcaag aaaagaauga acaagaaaua uuggaaauuag auuaauuggc aaguuugugg auuugguuua acauaaca aauuggcugugg uauuaauuaau uauucauaau gauaguagga ggcuugguag guuuuagaau aguuuuggcu guacuuucug uagugaauag aguuaggcag ggauauucac cauuaucgu uacacccac cucccaaucc cgaggggacc cgacaggccc gaaggaaauag aagaagaagg uggagagaga gacagagaca gauccauucg auuagugaac ggaucuuuag cacuuaucug ggacgaucug cgagccug uccucuucag cuaccaccgc uugagagacu uacuucuugau uguacgagg auuugggaaac uucugggacg cagggggugg gaagcccuu aauauuggug gaaucuccua caguauugga gucaggagc aagaaauuagc gcuguuuagc ugcuuaugc cacagcuaua gcaguagcug agggagaga uaggguuuaa gaaguaguac aaggagcuua uagagcuauu cgcccacauac cuagaagaa aagacaggc uuggaaagga uuuugcuaua agaugggugg caagugguca aaaaguagug ugguuggaag ggcugcugua agggaaagaa ugagacgagc ugagccagca gcagauuggg uggagcagc aucucgagac cuagaaaaac auggagcaau cacaaguagc aacacagcag cuaacaaugc ugauuugugc uggcuuaga cacaagagga ggaggaggug guuuuccag ucacaccuca gguacuuua agaccaauga cuuacaggc agcuguagau cuuagccacu uuuuuaaaga aaaggggggc cuggaaggc uauuucacuc ccaaacgaaga caagauaucc uugaucugug gauuaccac acacaaggc acuucccuga uuagcagaac uacacaccag ggccaggggau cagauuacca cugacuuug gauuggcua caagcuaua ccagugagc cuuguuuacac ccugugagcc cagagaaguu agaagaagcc gaggguugac agccgcccug caagaacugc ugacauugc gcaugggcugc uggaguacuu gcccggcug ggcgggacug uuuuuggccug uacugggucu cucugguuag accagaucug uacugggucu accagaucug agccuggggag cuc	5160 5220 5280 5340 5400 5460 5520 5580 5640 5700 5760 5820 5880 5940 6000 6060 6120 6180 6240 6300 6360 6420 6480 6540 6600 6660 6720 6780 6840 6900 6960 7020 7080 7140 7200 7260 7320 7380 7440 7500 7560 7620 7680 7740 7800 7860 7920 7980 8040 8100 8160 8220 8280 8340 8400 8460 8520 8580 8640 8700 8760 8820 8880 8933
---	---	--

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

5 &lt;223&gt; Sequence of the IAC-Asrc pseudo target

&lt;221&gt; mutation

&lt;222&gt; (4135)...(4155)

&lt;223&gt; Mutated positions: 4135, 4140-1, 4145, 4150, 4152-3, 4155

10

&lt;400&gt; 4

15	gagcucucuc gacgcaggac ucggcuugcu gaagcgcgcga cggcaagagg cgaggggcgg cgacugguga guacgcacaa aauuuugacu agcggaggcu agaaggagag agaugggugc gagagcguca guauuaagcg ggggagaaau agaucgaugg gaaaaaaaauc gguuaaggcc agggggaaag aaaaaauaua auuuaaaaca uauaguauugg gcaaggcagg agcuagaacg auucgcaguu auuccuggcc uguuagaaac aucagaaggc uguagacaaa uacugggaca gcuacaacca ucccuucaga caggaucaga agaacuuuaga ucauuauaua auacaguagc aaccucuau ugugugcauc aaaggauaga gauaaaagac accaaggaaag cuuuagacaa gauagaggaa gagcaaaaca aaaguaagaa aaaagcacag caagcggcagcugacacagg acacagcagu caggucagcc aaaaauaccc uauagugcag aacaucagg ggcaaauggu acaucaggcc auauaccuaa gaacuuuuaa ugcaggugga aaguaguag aagagaaggc uuucagccca gaaguauac ccauguuuuc agcauuauca gaaggagcga ccccaacaaga uuuuaacacc augcuuaaca caggggggg acaucaagca gccaugcaaa uguuaaaaga gaccaucaau gaggaaagcug cagaccaggc aaccaagggg aagugacaua gcaggaaacua ugcaccaggc cagaugagag ucaggaacaa auaggaugga uaccaaaaaaa uccaccuauc aagauggaua auccugggau ggacauuaaga caaggaccaa ccauguuuuc aagacccu ucuaagagcc gagcaagcuu cccaaauugcg aaccaggauu uguuagggccu agaagaaauug augacagcau ggcuugaagca augagccaa ugacaaac uaggaaacca agaaagaugg aaaaugcagg gcccuaugga gaaagauugu acugagagac aaggccaggg auuuuuucuuc cagaccag caccaggag ccaacagccc ucccccucag aacgaggc acucuuuggc aacgaccccu uuagauacag gaggcaga ccaaaaaua uagggggaaau auagaaauuc guggacauaa auaaauugga gaaaucuguu auugagacug uaccaguaaa ccauuugacag aaaaaaaauu gggaaaauu aaaaaagaca guacuaauu caaaaaauugg caagacuuuc gggaaugcu uacuac ucaguaua uacuggaau gggugugca uuuuuucag aggaaguaua cugcauuuac caguacaaug acaaaaaucu uagagccuuu gaugauuugu gaugauuugu auguaggauc cugagacaac cugagacaac aucuguugag ccuccauuucc ccuccauuucc uuuggauggg gugcugccag aaaaaagacag aauugggca ggaaccaaag cacuaacaga gaaaacagag agauucuaaa uuauuagcg aaaaacagaa ccauuuaaaa aucugaaaac guaaaaacaa uaacagaggc aagacuccua auuuaaaacu	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3120
----	--	---

55



5	gcaaagagaa gaguggugca gagagaaaaaa agagcagugg gaaauaggagc uuuguuuccuu ggguucuugg gaggcagg aagcacuaug ggccgcgcgu caauggacgcu gacgguacag gccagacaau uauugucugg uauagugcag cagcagaaca auuugcugag ggcuaauugag gcfgaacagc aucuguugca acucacaguc ugaaaaaauca agcagcucca ggcaagaauc cuggcugugg aaagauaccu aaaggaucaa cagcuccugg ggauuuugggg uugcucugga aaacuauuu gcaccacugc ugugccuugg aauugcuaug ggaguaauua auctucuggaa cagauuuugga auaacaugac cuggauggag ugaaaaaacaacaa uuacacaagc uuauauacacu ccuuauuuga agaaucgcaa aaccagcaag aaaagaauga acaagaauua uuggaaauuag auaaaugggc aaguuuugugg aauugguuua acauaacaaa uuggcugugg uauauaaaaau uauucauauu gauaguagga ggcuugguag guuuuagaau aguuuuugcu guacuuucug uagugaauag auuuaggcag ggauauucac cauuauucguu ucagacccac cuuccaaucu cgaggggacc cgacaggccc gaaggaaauag aagaagaagg ugagagaga gacagagaca gauccauucg aauagugaac ggaucuuuag cacuuauucug ggacgaucug cgaggccugu gccucuucag cuaccacccgc uugagagac uacucuugau uguuacgagg auuguggaac uucugggacg caggggggg gaagcccuu aauauuuggug gaaucuccua caguauugga gucaggagcu aagaauagu gcuguuagcu ugcucaauugc cacagcuaua gcaguagcug agggggacaga uaggguuuaa gaaguaguac aaggagcuua uagagcuauu 15 cgccacauac cuagaagaau aagacagggc uuggaaaagga uuuugcuaua agaugggugg caagugguca aaaaguagug ugguugga ggcugcugua agggaaagaa ugagacgagc ugagccagca gcagaugggg ugaaaggcagc auctucgagac caaaaaaac auggagcaau cacaaguagc aacacagcag cuaacaaugc ugauuugugcc uggcuagaag cacaagagga ggaggaggug gguuuuccag ucacaccuuu gguaccuuuua agaccaaua cuuacaaggc 20 agcuguagau cuuagccacu uuuuaaaaga aaagggggga cuggaaggc uauucacuc ccaacgaaga caagauaucc ugaucugug gaucuaccac acacaaggc acuuuccuga uuagcaaaac uacacaccag ggccagggau cagauaucca cugaccuuuug gauggugcua caagcuaua ccaguugagc cagagaauu agaagaagcc aacaaaggag agaacaccag cuuguuacac ccugugagcc ugcauggaa ggaugacccg gagagagaag uguuagagug gagguuugac agccgcccug cauuucauca cauggcccg gagcugcuauc cggaguacuu caagaacugc ugacauucgag cuugcuacaa gggacuuucc gcuggggacu uuccaggag 25 gcguggccug ggcgggacug gggaguggcg agcccucaga uccugcaaua aagcagcugc uuuuuugccug uacugggucu cucugguuag accagauug agccugggag cuc	7140 7200 7260 7320 7380 7440 7500 7560 7620 7680 7740 7800 7860 7920 7980 8040 8100 8160 8220 8280 8340 8400 8460 8520 8580 8640 8700 8760 8820 8880 8933
---	---	--

&lt;210&gt; 5

&lt;211&gt; 30

30 &lt;212&gt; DNA

&lt;213&gt; HIV

&lt;220&gt;

&lt;221&gt; source

35 &lt;222&gt; (1) ... (30)

&lt;223&gt; Sequence of AE(+)4134 HIV-specific probe.

&lt;400&gt; 5

40 ccacaatttt aaaaagaaaaag gggggatcgg

30

&lt;210&gt; 6

&lt;211&gt; 67

45 &lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Sequence of (-)3837 A30 capture probe.

50 &lt;400&gt; 6

ccctgtttct gctggaataa cttctgcttc tatatttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa	60
---	----

67

55 &lt;210&gt; 7

&lt;211&gt; 57

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Sequence of the (-)4258 A30 capture probe.

&lt;400&gt; 7

5

tctgctgtcc ctgtaataaa cccgtttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

57

&lt;210&gt; 8

&lt;211&gt; 22

10

&lt;212&gt; DNA

&lt;213&gt; HIV

&lt;220&gt;

&lt;221&gt; source

15

&lt;222&gt; (0)...(0)

&lt;223&gt; Sequence of the AE(+)4134b probe

&lt;400&gt; 8

20

ccacaatttt aaaagaaaaag gg

22

&lt;210&gt; 9

&lt;211&gt; 8933

25

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Sequence of the IAC-Bscr pseudo target

30

&lt;221&gt; mutation

&lt;222&gt; (4140)...(4159)

&lt;223&gt; Mutated positions: 4140-42, 4145-47, 4152, 4156-57, 4159

35

&lt;400&gt; 9

40

45

50

55

5	gagcucucuc gacgcaggac ucggcuugcu gaagcgcgca cggcaagagg cgaggggcgg cgacugguga guacgccaaa aauuuugacu agcggaggcu agaaggagag agaugggugc gagagcguca guauuaagcg ggggagaaau agaucgaugg gaaaaaaaauc gguuaaggcc agggggaaag aaaaaauaua auuuaaaaca uauaguauugg gcaagcaggg agcuagaacg auucgcaguu aauccuggcc uguuagaaac aucagaaggc uguagacaaa uacugggaca gcuacaacca ucccuucaga caggaucaga agaacuuuaga ucauuauua auacaguagc aaccuccuau ugugugcauc aaaggauaga gauaaaaagac accaaggaag cuuuagacaa gauagaggaa gagaaaaca aaaguaagaa aaaagcacag caagcagcag cugacacagg acacagcagu caggucagcc aaaauuucc uauagugcag aacaucagg ggcaaauuggu acaucaggcc auaucaccua gaacuuuaaa ugcauggua aaaguaguag aagagaaggc uuucagccca gaaguaauac ccauguuuuc agcauuauca gaaggagcca ccccacaaga uuuaaacacc augcuuaaca caguggggg acaucaagca gccaugcaa uguuuaaaga gaccaucaau gaggaagcg cagaauggga uagaguacau ccagugcau cagggccuau ugcaccaggc cagaugagag aaccagggg aagugacaua gcaggaacua cuaguacccu ucaggaacaa auaggauuga ugacaaauua uccacuuaucc aguaggagg aaauuuauua aagauggaua auccugggau uaaauaaaaa aguaagaaug uauagccuua ccagcauuu ggacauaaga caaggacca aagaaccuuu uagagacaua guagaccgg ucuauaaaac 10 ucuaagagcc gagcaagcuu cacaggaggu aaaaaauugg augacagaaa ccuuguuggu ccaaaugcg aaccagauu guaagacaua uuuuaaagca uugggaccag cggcuacacu agaagaaaug augacagcau gucaggaggu aggaggaccc ggcuaaagg caagaguuuu ggcugaagca augagccaaug uaacaaaauac agcuaccaua augauggcaga gaggcaauuu uaggaaccaa agaaaaggug uuauguuu caauuguggc aaagaagggc acacagccag aaauugcagg gccccuagga aaaaggcug uuggaaaugu gggaaaggag gacaccaaau 20 gaaagauugu acugagagac aggcuaauuu uuuagggaag aucuggccuu ccuacaagg aaggccaggg aauuuuucuuc agagcagacc agagccaaaca gccccaccau uucuucagag cagaccagag ccaacagccc caccagaaga gagcuucagg ucugggguag agacaacaac uccccucag aaggaggagc cgauagacaa ggaacuguau cccuuuacuu cccucagauc acucuuuggc aacgaccccu cgucacaaua aagauagggg ggcaacuaaa ggaagcucua uuagauacag gaggcagauga uacaguauua gaagaauga guuugccagg aagauggaaa 25 caaaaaauga uagggggaaau uggagguuu aucaaaguaa gacaguaua ucagauacuc auagaaaauu gggacauaa agcuauaggu acaguauuag uaggaccuac accuguacac auauuuggaa gaaaucuguu gacucagauu gguugcacuu uaaaauuucc cauuagccu auugagacug uaccaguaaa auuuaagcca ggaauuggaug gccccaaagu uaaacaauugg ccauugacag aaaaaaaaau aaaagcaua guagaaauu guacagaaau ggaaaaggaa gggaaaauuu caaaaauugg gccugagaa ccauacaua cuccaguau ugcacauaaag aaaaaaagaca guacuaaua gagaauuuu guagauuuca gagaacuuua uaagagaacu 30	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160
---	--	--

35

40

45

50

55

5	caagacuucu	gggaaaguuca	auuaggaaua	ccacaucccg	caggguuaaa	aaagaaaaaaaa	2220
	ucaguaacag	uacuggaugu	gggugaugca	uauuuuuucag	uucccuuaga	ugaagacuuc	2280
	aggaaguua	cugcauuuac	cauaccuagu	auaaacaau	agacaccagg	gauuagauau	2340
	caguacaug	ugcuuccaca	gggauggaaa	ggaucaccag	caauauucca	auguagcaug	2400
	acaaaaaaucu	uagagccuuu	aaaaaaacaa	aaucaggaca	uaguuaucua	ucaauuacaug	2460
	gaugauuugu	auguaggauc	ugacuuagaa	auagggcagc	auagaacaaa	aauagaggag	2520
	cugagacaac	aucuguugag	guggggacuu	accacaccag	acaaaaaaaca	ucagaaaagaa	2580
	ccuccauucc	uuuggauggg	uuaugaacuc	cauccugaua	aauggacagu	acagccuuaua	2640
	gugcugccag	aaaaagacag	cuggacuguc	aaugacauac	agaaguuagu	ggggaaauug	2700
10	aauggggcaa	gucagauuu	cccagggauu	aaaguaaggc	aaauuauguaa	acuccuuaga	2760
	ggaaccaaag	cacuaacaga	aguauuacca	cuaacagaag	aagcagagc	agaacuggca	2820
	gaaaacagag	agauuucuua	agaaccagu	cauggagugu	auuaugaccc	aucaaaagac	2880
	uuaauagcg	aaaauacagaa	gcaggggcaa	ggccaauggg	cauauaaau	uuauaagag	2940
	ccuuuuuaaa	aucugaaaac	agggaaaauu	gcaagaauga	ggggugccca	cacuaauugau	3000
	guaaaacaa	uaacagaggc	agugcaaaaa	auaaccacag	aaagcauagu	aaauauuggg	3060
	aagacuccua	aaaauuuacu	acccauacaa	aagggaaacau	gggaaacaaug	guggacagag	3120
15	uuuuggcaag	ccaccuggau	uccugagugg	gaguuuguua	auaccccucc	uuuagugaaa	3180
	uuuugguacc	aguuagagaa	agaacccaua	guaggagcag	aaaccuuucua	uguagauggg	3240
	gcagcuaaca	gggagacuaa	auuagggaaa	gcaggaua	uuacuaacaa	aggaagacaa	3300
	aaggguugcc	cccuuacuua	cacaacaaa	cagaaaacug	aguuacaagc	aauuuauucua	3360
	gcuuugcagg	auucaggauu	agaaguuaac	auquaacag	acucacaaa	ugcauuuagg	3420
	aucauucaag	cacaaccaga	aaaaagugaa	ucagaguua	ucaauaaau	aauagaggcag	3480
20	uuuuaaaaaa	aggaaaagggu	uuuucaggca	uggguuaccag	cacacaaagg	aaauugggagga	3540
	aaugaacaag	uagauuaauu	agucagugc	ggaauucagga	aaauacuauu	uuuagauugg	3600
	auagauaagg	cccaagauga	acaugagaaa	uaucacagu	auuggagagc	aauggcuagu	3660
	gauuuuaacc	ugccaccugu	aguagcaaaa	gaaaauagu	ccagcuguga	uuaauugucag	3720
	cuaaaaggag	aagccaugca	uggacaagu	gacuguaguc	caggaaua	gcaacuagau	3780
	uguacacauu	uagaaggaaa	aguuauccug	guagcaguuc	auguagccag	uggauauaua	3840
25	gaagcagaag	uuauuccagc	agaaaacagg	cagggaaacag	cauuuuuuucu	uuuuaaaaaaua	3900
	gcaggaagau	ggccaguuua	aacaauacau	acagacaa	gcagcauuu	caccagugc	3960
	acgguuuagg	ccgcccuguu	gugggcggg	aucaagcagg	auuuuugga	uccuacaaau	4020
	ccccaaagc	uaggaguagu	agaaucua	aaauaaagaa	aaaagaaaa	uauaggacag	4080
	guaagagauc	aggcugaaca	ucuuaagaca	gcaguacaaa	uggcaguau	cauccagaaa	4140
	aatattgaa	aggggaagct	tggggguac	agugcagg	aaagaaau	agacauaaaua	4200
30	gcaacagaca	uacaaacuua	agaaauacaa	aaacaauuu	caaaaaauu	aaauuuucgg	4260
	guuuauuaca	gggacagcag	aaauccacu	uggaaaggac	cagcaa	ccucuggaaa	4320
	ggugaagggg	caguaguaau	acaagauua	agugacaua	aguagugcc	aagaagaaaa	4380
	gcaaagauca	uuagggauua	uggaaaacag	uggcaggug	augauuug	ggcaaguaga	4440
	caggauggg	auuagaacau	ggaaaagu	aguuaacac	cauaguau	uuucagg	4500
	aguuagggg	ugguuuuuaua	gacaucacu	ugaaacccu	cauccaaga	uaaguucaga	4560
	aguacacau	ccacuagg	augcuagau	gguaaua	acauauugg	gucugcauac	4620
35	aggagaaaga	gacuggcau	ugggucagg	agucuccau	gaauggagga	aaaagagaua	4680
	uagcacacaa	guagacccug	aacuagcaga	ccacuauu	caucuguau	acuuuugacug	4740
	uuuuucagac	ucugcuaua	gaaaggccu	auuaggacac	auguuaggc	cuagguguga	4800
	auaucaagca	ggacauaaca	agguaggau	ucuacauu	uuggcacu	cagcauuuau	4860
	aacacaaaa	aagauaaacg	cacuuuugcc	uaguguac	aaacugacag	aggauagaug	4920
	gaacaagcc	cagaagacca	agggcccac	agggagcc	acaaua	gacacuagag	4980
40	cuuuuagg	agcuaaag	ugaagcugu	agacuuuuc	cuaggauu	gcuccauggc	5040
	uuagggcaac	auaucuauga	acuuauugg	gauacu	gaggug	agccauuaau	5100
	agaauuc	aaaaacugc	guuuauccu	uuucagaau	gggugugc	auagcagaau	5160
	aggcguuacu	cgacagagga	gagcaagaa	uggagcc	agauccu	cuagagccu	5220
	ggaagcaucc	aggaagucag	ccuaaaacug	cuuguac	uugcuauu	aaaaagugu	5280
	gcuuucuuacu	ccaaguuu	uucauaacaa	aagccuu	caucuccu	ggcaggaaga	5340
45	agcggagaca	gchgacaga	ccuccu	gcagucag	ucaucaagu	ucucuauc	5400
	agcaguau	aguacaugua	augcaaccu	uacaaau	aguagac	uuaguaguag	5460
	caauuaau	agcaauagu	guguggucc	uaguau	agaaaua	aaaaauuuua	5520
	gacaaagaaa	aaugacacgg	uuuauugau	gacuaau	aagac	gacagugg	5580
	augagaguga	aggagaaaua	ucagcacu	uggagau	gguggag	gggcacca	5640
	cuccuugg	uguuugau	cuguaguc	acagaaaa	ugggguc	agucuaau	5700
	gggguaccu	uguggaagg	agcaacc	acucua	gugcau	ugcuaagca	5760
50	uaugauacag	agguacaua	uguuugg	acacu	guguacc	agacccca	5820
	ccacaagaag	uaguauugg	aaaugug	gaaaauu	acaug	aaugacau	5880
	guagaacaga	ugcaugag	uauauc	uuau	agac	gccaugug	5940
	aauuaaccc	cacucugugu	uaguuaa	ugc	gac	uacuaau	6000
	aauguagua	gcgggagaau	gauua	uag	aaag	ucuuucaau	6060
	aucagcacaa	gcauaagagg	uaagg	aaagaa	gaga	ucuuuugau	6120

5	'auuaauaccää uagauuaugä uacuaccagc uäuacguuga caaguuguaa caccucaguc auuacacagg ccuguccaaa gguauccuuu gagccaaauuc ccauacauua uugugccccg gcugguuuug cgauucuaaa auguaauuaa aagacguuca auggaacagg accauguaca aaugucagca caguacaaug uacacaugga uuaggccag uaguaucaac ucaacugcug uuaauuggca gucuggcaga agaagaggua guaauuugau cugccaaauu cacagacaau gcuaaaacca uaauguaca gcugaacca ucuguagaaa uuaauuguac aagacccaaac aacaauacaa gaaaaguau ccguauccag agaggaccag ggagagcaau uguuacaaua ggaaaaauag gaaaauagag acaagcacau uguaacauua guagagcaaa auggaauaac acuuuuaaac agauagauag caaauuaaga gaacaauuug gaaaauauaa aacaauaauc uuuaagcagu ccucaggagg ggacccagaa auuguaacgc acaguuuuaa uuguggaggg gaauuuuucu acuguaauuc aacacaacug uuaauuaguau cuugguuuuaa uaguacuugg aguacuaaag ggucaaaauua cacugaagga agugacacaa ucacccuccc augcagaaaua aaacaaauua uaaacaugug gcaggaaguua ggaaaagcaa uguauugccc ucccaucagu ggacaaaauua gauguucauc aaaaauuaca gggcugcuau uaacaagaga uggugguaau agcaacaaug aguccgagau cuucagaccu ggaggaggag auuugagggc caauuggaga agugaauuuau auaaauauaa aguaguaaaa auugaaccau uaggaguagc acccacaag gcaaagagaa gaguggugca gagagaaaa agagcagugg gaaauaggagc uuuguuccuu ggguucuugg gacgacgagg aagcacuaug ggcgcagcgu caaugacgcu gacgguacag gccagacaaau uauugucugg uauagugcag cagcagaaca auiugcugag ggcuaauugag gcgcaacagc aucuguuugca acucacaguc uggggcauca acgcgcucca ggcagaaauc cuggcugugg aaagauaccu aaaggaucaa cagcuccugg ggauuugggg uugcucugga aaacucauuu gcaccacugc ugugccuugg aaugcuaguu ggaguauuaa aucucuggaa cagauuugga auuacaaugac cuggauggag ugggacagag aaaaauacaa uuacacaagc uuuaauacacu ccuaauuuga agaaucgcua aaccagcaag aaaagaaua acaagaauua uuggaaauuag auaaauugggc aaguuugugg aauuugguuua acauaaacaaa uuggcugugg uuuauaaaaau uauucauauu gauaguagga ggcuugguag guuuaagaaau aguuuuugcu guacuuucug uagugauaag aguuaggcag ggauuuucac cauuaucguu ucagacccac cucccaaucc cgaggggacc gacagggacc gaaggaaug aagaagaagg uggagagaga gacagagaca gauccauucg cggagccugu gccucuucag auuuggaac aauuugcuaug cggagccuug cuaccaccgc cuaccaccgc uugagagacu uacuugugc uguaacgc auuggugaac uucugggacg cagggggugg gaagcccua aauuuggug gaaucuccua caguauugga gucaggagcu cagaaauagu gcuuauagc ugcuauaucg cacagcuaua gcaguagcug agggacaga uaggguuuaa gaaguaguac aaggagcua uagagcuaau cgccacauac cuagaagaa aagacaggc uuggaaagga uuuugcuaau agaugggugg caagugguca aaaaguagug ugguugga augggacg gccuugcugua agggaaagaa ugagacgagc ugagccagca gcagaugggg ugggacgac aucucgagac cuagaaaaac auggagcaau cacaaguagc aacacagcg cuaacaaugc ugaauugugcc uggcuaagag cacaagagga ggaggaggug gguuuccag ucacaccuca gguaccuuua agaccaaua cuuacaaggc agcuguagau cuuagccac uuuuaaaga aaaggggggc cuggaagggc uauucacuc ccaacgaaga caagauaucc uugaucugug gaucuaccac acacaaggc acuucccuga uuagcagaac uacacaccag ggccaggga cagauaucca cugaccuuug gauggugcua caagcuagua ccaguugagc cagagaaguu agaagaagcc aacaaaggag agaacaccag cuuguuuacac ccugugagcc ugcauggaa ggaugaccgc gagagagaag uguuagagug gaggguugac agccgcuuag cauucuauca cauggcccga gacugcugcauc cggaguacuu caagaacugc ugacauucg cuugcuacaa gggacuuucc gcuggggacu uuccaggag gcguggccug ggccggacug gggaguggcg agcccucaga uccugcauau aagcagcugc uuuugccug uacugggcuu accagaucug agccugggag cuc	6180 6240 6300 6360 6420 6480 6540 6600 6660 6720 6780 6840 6900 6960 7020 7080 7140 7200 7260 7320 7380 7440 7500 7560 7620 7680 7740 7800 7860 7920 7980 8040 8100 8160 8220 8280 8340 8400 8460 8520 8580 8640 8700 8760 8820 8880 8933
40		

## Claims

45 1. A method of quantifying analyte polynucleotides present in a test sample, comprising the steps of:

50 combining a predetermined amount of a test sample with a predetermined amount of a pseudo target, said test sample containing an unknown amount of analyte polynucleotide;

55 co-amplifying in a polynucleotide amplification reaction the pseudo target and any of the analyte polynucleotide contained in said test sample to produce a collection of amplification products, said collection including both an analyte amplicon if said test sample contained the analyte polynucleotide and a pseudo target amplicon; and

55 quantifying the analyte amplicon without reference to the amount of pseudo target amplicon, whereby the quantity of analyte amplicon is related in a manner that is dose dependent on the unknown amount of the analyte polynucleotide contained in said test sample.

2. The method of Claim 1, wherein the step for quantifying comprises hybridizing said collection of amplification

products from the co-amplifying step with a labeled probe specific for the analyte amplicon but not the pseudo target amplicon and then detecting any labeled probe that specifically hybridized the analyte amplicon.

5       3. The method of Claim 2, wherein said polynucleotide amplification reaction in the co-amplifying step is selected from the group consisting of a Transcription Mediated Amplification reaction, a NASBA reaction and a Polymerase Chain Reaction.

10      4. The method of Claim 3, wherein said polynucleotide amplification reaction is the Transcription Mediated Amplification reaction.

15      5. The method of either Claim 3 or Claim 4, further comprising a step for releasing nucleic acids contained in said test sample, said releasing step being performed preliminary to said combining step.

15      6. The method of Claim 5, further comprising a step for capturing said analyte polynucleotide onto a solid support prior to said co-amplifying step.

7. The method of Claim 6, wherein the solid support is a bead derivatized with a synthetic polynucleotide.

20      8. The method of Claim 6, wherein the predetermined amount of said pseudo target in the combining step ranges from between  $1.0 \times 10^3$  and  $2 \times 10^8$  molecules, preferably from between  $1.0 \times 10^4$  and  $2 \times 10^8$  molecules, and more preferably from between  $1.0 \times 10^5$  and  $2 \times 10^8$  molecules.

25      9. The method of Claim 5, wherein the biological specimen is a blood sample or a plasma sample and wherein said nucleic acids comprise viral nucleic acids.

10. The method of Claim 9, wherein the analyte polynucleotide is released from HIV virions.

30      11. The method of Claim 5, wherein the predetermined amount of the pseudo target in the combining step is between  $1.0 \times 10^3$  and  $2 \times 10^8$  molecules, preferably from between  $1.0 \times 10^4$  and  $2 \times 10^8$  molecules, and more preferably from between  $1.0 \times 10^5$  and  $2 \times 10^8$  molecules.

35      12. The method of Claim 4, further comprising a step for isolating said analyte polynucleotide and said pseudo target after the combining step and before the co-amplifying step.

40      13. The method of Claim 4, wherein the predetermined amount of the pseudo target is between  $1.0 \times 10^3$  and  $2 \times 10^8$  molecules, preferably from between  $1.0 \times 10^4$  and  $2 \times 10^8$  molecules, and more preferably from between  $1.0 \times 10^5$  and  $2 \times 10^8$  molecules.

45      14. The method of Claim 2, wherein said labeled probe is labeled with acridinium ester.

40      15. The method of Claim 14, wherein the quantifying step comprises measuring by luminometry the probe labeled with acridinium ester that specifically hybridized the analyte amplicon.

50      16. The method of Claim 1, further comprising a step for consulting a standard curve that relates pre-amplification amounts of analyte polynucleotide and post-amplification amounts of analyte amplicon..

55      17. The method of Claim 4, further comprising a step for consulting a standard curve that relates pre-amplification amounts of analyte polynucleotide and post-amplification amounts of analyte amplicon.

50      18. The method of Claim 15, further comprising a step for consulting a standard curve that relates pre-amplification amounts of analyte polynucleotide and post-amplification amounts of analyte amplicon.

55      19. The method of Claim 4, wherein the Transcription Mediated Amplification reaction employs a paired set of oligonucleotide primers have the sequences of SEQ ID NO:1 and SEQ ID NO:2.

55      20. The method of Claim 19, wherein the pseudo target has a polynucleotide sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:9.

21. A method for relating pre-amplification amounts of analyte polynucleotide and post-amplification amounts of analyte amplicon, said method comprising the steps of:

5           obtaining a plurality of control samples, wherein each of the control samples has a different predetermined amount of an analyte polynucleotide;  
 combining each of said plurality of control samples with a constant predetermined amount of a pseudo target to result in a plurality of mixed control samples;  
 10          co-amplifying in a plurality of amplification reactions both the pseudo target and the analyte polynucleotide present in each of said plurality of mixed control samples to produce a collection of amplification products that include a pseudo target amplicon and an analyte amplicon;  
 quantifying the analyte amplicon for each of said plurality of amplification reactions without reference to the amount of pseudo target amplicon present in said collection of amplification products; and  
 15          preparing a standard curve having the different predetermined amounts of said analyte polynucleotide plotted against the quantified amounts of said analyte amplicon produced in each of said plurality of amplification reactions, thereby relating the pre-amplification amounts of said analyte polynucleotide in said plurality of control samples and the post-amplification amounts of analyte amplicon synthesized in the plurality of amplification reactions.

22. The method of Claim 1 or Claim 21, further comprising a step for detecting the pseudo target amplicon.

20          23. The method of Claim 6 or Claim 21, wherein said analyte polynucleotide is a viral polynucleotide.

24. The method of Claim 23, wherein the viral polynucleotide is an HIV polynucleotide.

25          25. The method of Claim 21, wherein said constant predetermined amount of said pseudo target is between  $1.0 \times 10^3$  and  $2 \times 10^8$  molecules, preferably from between  $1.0 \times 10^4$  and  $2 \times 10^8$  - molecules, and more preferably from between  $1.0 \times 10^5$  and  $2 \times 10^8$  molecules.

30          26. The method of Claim 21, wherein said plurality of amplification reactions in the co-amplifying step is selected from the group consisting of a plurality of Transcription Mediated Amplification reactions, a plurality of NASBA reactions and a plurality of PCR reactions.

35          27. The method of Claim 26, wherein said plurality of amplification reactions in the co-amplifying step are a plurality of Transcription Mediated Amplification reactions.

40          28. The method of Claim 26 or Claim 27, wherein the quantifying step comprises hybridizing said collection of amplification products from the co-amplifying step with a labeled probe specific for the analyte amplicon but not the pseudo target amplicon and then quantitatively detecting any labeled probe that specifically hybridized the analyte amplicon.

45          29. The method of Claim 28, wherein the labeled probe is labeled with acridinium ester.

30. The method of Claim 28, further comprising a step for capturing said analyte polynucleotide onto a solid support prior to said co-amplifying step.

45          31. A method of determining whether a biological sample contains an analyte polynucleotide, comprising the steps of:

50           obtaining a biological sample to be tested for the presence of the analyte polynucleotide;  
 combining the biological sample with a pseudo target to result in a mixed sample;  
 isolating nucleic acids from the mixed sample, whereby there is obtained a collection of molecules comprising the pseudo target and any of said analyte polynucleotide present in the biological sample;  
 conducting a polynucleotide amplification reaction to co-amplify the pseudo target and any of said analyte polynucleotide contained in said collection of molecules to produce amplification products, whereby pseudo target amplicons are formed, and whereby analyte amplicons are formed if said collection of molecules included said analyte polynucleotide;  
 55          detecting in said amplification products any of said analyte amplicons without detecting said pseudo target amplicons; and  
 determining that the biological sample contains said analyte polynucleotide if said analyte amplicons are de-

tected in the amplification products.

32. The method of Claim 31, wherein the amplification reaction is selected from the group consisting of a Transcription Mediated Amplification reaction, a NASBA reaction and a PCR reaction.

5 33. The method of Claim 32, wherein the amplification reaction is a Transcription Mediated Amplification reaction.

10 34. The method of either Claim 32 or Claim 33, wherein the detecting step comprises first hybridizing a labeled polynucleotide probe having binding specificity for the analyte amplicons and then measuring the extent of specific binding of the labeled polynucleotide probe and the analyte amplicons.

15 35. The method of Claim 34, wherein the isolating step comprises immobilizing said pseudo target and said analyte polynucleotide to a solid support.

36. The method of Claim 34, wherein the detecting step comprises detecting by luminometry.

15 37. The method of Claim 36, wherein the analyte polynucleotide is from HIV virions.

38. The method of Claim 37, wherein the pseudo target has a sequence selected from the group consisting of SEQ ID No:4 and SEQ ID No:9.

#### Patentansprüche

25 1. Ein Verfahren zum Quantifizieren eines in einer Testprobe vorhandenen Polynukleotidanalyten, das die Schritte umfasst :

30 Kombinieren einer vorgegebenen Menge einer Testprobe mit einer vorgegebenen Menge eines Pseudoziels, wobei die Testprobe eine unbekannte Menge an Polynukleotidanalyten enthält;

30 Co-Amplifizieren des Pseudoziels und jedes der Polynukleotidanalyten, die in der Testprobe enthalten sind, in einer Polynukleotid-Amplifizierungsreaktion, um eine Sammlung von Amplifizierungsprodukten zu erzeugen, wobei die Sammlung sowohl ein Analyt-Amplikon, wenn die Testprobe das Polynukleotidanalyt enthält, als auch ein Pseudoziel-Amplikon einschließt; und

35 Quantifizieren des Analyt-Amplikons ohne Bezug auf die Pseudoziel-Amplikongruppe, wobei die Menge an Analyt-Amplikon in einer Dosis-abhängigen Weise von der unbekannten Menge des Polynukleotidanalyten, der in der Testprobe enthalten ist, abhängig ist.

40 2. Das Verfahren gemäß Anspruch 1, wobei der Quantifizierungsschritt das Hybridisieren der Sammlung von Amplifizierungsprodukten aus dem Co-Amplifizierungsschritt an eine markierte Probe, die für das Analyt-Amplikon, aber nicht für das Pseudoziel-Amplikon spezifisch ist, und das folgende Detektieren jeder markierten Probe, die spezifisch an das Analyt-Amplikon hybridisiert, umfasst.

45 3. Das Verfahren gemäß Anspruch 2, wobei die Polynukleotidamplifizierungsreaktion im Co-Amplifizierungsschritt aus der Gruppe, die aus einer transkriptionsvermittelten Amplifizierungsreaktion, einer NASBA-Reaktion und einer Polymerase-Kettenreaktion besteht, ausgewählt wird.

4. Das Verfahren gemäß Anspruch 3, wobei die Polynukleotidamplifizierungsreaktion eine transkriptionsvermittelte Amplifizierungsreaktion ist.

50 5. Das Verfahren gemäß entweder Anspruch 3 oder 4, das des Weiteren einen Schritt für das Freisetzen der Nukleinsäuren, die in der Testprobe enthalten sind, umfasst, wobei der Freisetzungsschritt vor dem Kombinierungsschritt durchgeführt wird.

55 6. Das Verfahren gemäß Anspruch 5, das des Weiteren einen Schritt für das Einfangen von dem Polynukleotidanalyten auf einem festen Träger vor dem Co-Amplifizierungsschritt umfasst.

7. Das Verfahren gemäß Anspruch 6, wobei der feste Träger ein Kugelchen ist, das mit einem synthetischen Polynukleotid derivatisiert ist.

8. Das Verfahren gemäß Anspruch 6, wobei die vorgegebene Menge von dem Pseudoziel in dem Kombinierungsschritt in dem Bereich zwischen  $1,0 \times 10^3$  und  $2 \times 10^8$  Molekülen, vorzugsweise zwischen  $1,0 \times 10^4$  und  $2 \times 10^8$  Molekülen, und noch bevorzugter zwischen  $1,0 \times 10^5$  und  $2 \times 10^8$  Molekülen liegt.
- 5 9. Das Verfahren gemäß Anspruch 5, wobei die biologische Probe eine Blutprobe oder eine Plasmaprobe ist, und wobei die Nukleinsäuren virale Nukleinsäuren umfassen.
- 10 10. Das Verfahren gemäß Anspruch 9, wobei das Polynukleotidanalyt von HIV-Virionen freigesetzt wird.
- 15 11. Das Verfahren gemäß Anspruch 5, wobei die vorgegebene Menge von Pseudoziel in dem Kombinierungsschritt zwischen  $1,0 \times 10^3$  und  $2 \times 10^8$  Molekülen, vorzugsweise zwischen  $1,0 \times 10^4$  und  $2 \times 10^8$  Molekülen und noch bevorzugter zwischen  $1,0 \times 10^5$  und  $2 \times 10^8$  Molekülen liegt.
- 15 12. Das Verfahren gemäß Anspruch 4, das des Weiteren einen Schritt zum Isolieren von dem Polynukleotidanalyten und dem Pseudoziel nach dem Kombinierungsschritt und vor dem Co-Amplifizierungsschritt beinhaltet.
- 20 13. Das Verfahren gemäß Anspruch 4, wobei die vorgegebene Menge des Pseudoziels zwischen  $1,0 \times 10^3$  und  $2 \times 10^8$  Molekülen, vorzugsweise zwischen  $1,0 \times 10^4$  und  $2 \times 10^8$  Molekülen, noch bevorzugter zwischen  $1,0 \times 10^5$  und  $2 \times 10^8$  Molekülen liegt.
- 20 14. Das Verfahren gemäß Anspruch 2, wobei die markierte Probe mit einem Acridiniumester markiert ist.
- 25 15. Das Verfahren gemäß Anspruch 14, wobei der Quantifizierungsschritt das Messen der Probe, die mit Acridiniumester markiert ist und spezifisch an das Analyt-Amplikon hybridisiert, über Luminometrie umfasst.
- 25 16. Das Verfahren gemäß Anspruch 1, das des Weiteren einen Schritt für das Hinzuziehen einer Standardkurve, die die Mengen an Polynukleotidanalyt vor und die Mengen an Analyt-Amplikon nach der Amplifikation in Beziehung setzt, umfasst.
- 30 17. Das Verfahren gemäß Anspruch 4, das des Weiteren einen Schritt für das Hinzuziehens einer Standardkurve, die die Mengen an Polynukleotidanalyt vor und die Mengen an Analyt-Amplikon nach der Amplifikation in Beziehung setzt, umfasst.
- 35 18. Das Verfahren gemäß Anspruch 15, das des Weiteren einen Schritt für das Hinzuziehens einer Standardkurve, die die Mengen an Polynukleotidanalyt vor und die Mengen an Analyt-Amplikon nach der Amplifikation in Beziehung setzt, umfasst.
- 40 19. Das Verfahren gemäß Anspruch 4, wobei die transkriptionsvermittelte Amplifizierungsreaktion einen gepaarten Satz von Oligonukleotidprimern verwendet, die die Sequenzen von SEQ ID NO:1 und SEQ ID NO:2 besitzen.
- 40 20. Das Verfahren gemäß Anspruch 19, wobei das Pseudoziel eine Polynukleotidsequenz besitzt, die aus der Gruppe, die aus SEQ ID NO:4 und SEQ ID NO:9 besteht, ausgewählt wird.
- 45 21. Ein Verfahren zum In-Beziehung-setzen der Präamplifikationsmenge an Polynukleotidanalyt und der Postamplifikationsmenge an Analyt-Amplikon, wobei die Methode die Schritte umfasst:
  - Erhalten einer Vielzahl von Kontrollproben, wobei jede der Kontrollproben eine unterschiedliche vorgegebene Menge eines Polynukleotidanalyten besitzt;
  - 50 Kombinieren von jeder von der Vielzahl von Kontrollproben mit einer konstanten vorgegebenen Menge eines Pseudoziels, um zu einer Vielzahl von gemischten Kontrollproben zu führen;
  - 55 Co-Amplifizieren sowohl des Pseudoziels als auch des Polynukleotidanalyts, das in jeder von der Vielzahl von gemischten Kontrollproben enthalten ist, in einer Vielzahl von Amplifizierungsreaktionen, um eine Sammlung von Amplifizierungsprodukten zu erzeugen, die ein Pseudoziel-Amplikon und ein Analyt-Amplikon einschließen;
  - 55 Quantifizieren des Analyt-Amplikons für jede von der Vielzahl von Amplifizierungsreaktionen ohne Bezug auf die Menge an Pseudoziel-Amplikon, die in der Sammlung von Amplifizierungsprodukten vorhanden ist; und Erstellen einer Standardkurve, in der die verschiedenen vorgegebenen Mengen von dem Polynukleotidanalyten gegen die quantifizierten Mengen von dem Analyt-Amplikon, das in jeder von der Vielzahl von Amplifi-

zierungsreaktionen erzeugt wurde, aufgetragen sind, und **dadurch** das In-Beziehung-setzen der Mengen von dem Polynukleotidanalyten in der Vielzahl von Kontrollproben vor und die Menge von Analyt-Amplikons, die in der Vielzahl von Amplifizierungsreaktionen synthetisiert wurden, nach der Amplifikation.

5        22. Das Verfahren gemäß Anspruch 1 oder Anspruch 21, das des Weiteren einen Schritt zum Detektieren des Pseudoziel-Amplikons umfasst.

10      23. Das Verfahren gemäß Anspruch 6 oder Anspruch 21, wobei das Polynukleotidanalyt ein virales Polynukleotid ist.

15      24. Das Verfahren gemäß Anspruch 23, wobei das virale Polynukleotid ein HIV-Polynukleotid ist.

20      25. Das Verfahren gemäß Anspruch 21, wobei die konstante vorgegebene Menge von dem Pseudoziel zwischen 1,0 x 10<sup>3</sup> und 2 x 10<sup>8</sup> Molekülen, vorzugsweise zwischen 1,0 x 10<sup>4</sup> und 2 x 10<sup>8</sup> Molekülen, und noch bevorzugter zwischen 1,0 x 10<sup>5</sup> und 2 x 10<sup>8</sup> Molekülen liegt.

25      26. Das Verfahren gemäß Anspruch 21, wobei die Vielzahl von Amplifizierungsreaktionen im Co-Amplifizierungsschritt aus der Gruppe, die aus einer Vielzahl von transkriptionsvermittelten Amplifizierungsreaktionen, einer Vielzahl von NASBA-Reaktionen und einer Vielzahl von PCR-Reaktionen besteht, ausgewählt wird.

30      27. Das Verfahren gemäß Anspruch 26, wobei die Vielzahl von Amplifizierungsreaktionen im Co-Amplifizierungsschritt eine Vielzahl von transkriptionsvermittelten Amplifizierungsreaktionen ist.

35      28. Das Verfahren gemäß Anspruch 26 oder Anspruch 27, wobei der Quantifizierungsschritt das Hybridisieren der Sammlung von Amplifikationsprodukten aus dem Co-Amplifizierungsschritt mit einer markierten Probe, die für das Analyt-Amplikon, aber nicht für das Pseudoziel-Amplikon spezifisch ist, und das folgende quantitative Detektieren jeder markierten Probe, die spezifisch an das Analyt-Amplikon hybridisiert, umfasst.

40      29. Das Verfahren gemäß Anspruch 28, wobei die markierte Probe mit einem Acridiniumester markiert ist.

45      30. Das Verfahren gemäß Anspruch 28, das des Weiteren einen Schritt für das Einfangen von dem Polynukleotidanalyten auf einem festen Träger vor dem Co-Amplifizierungsschritt umfasst.

50      31. Ein Verfahren zur Bestimmung, ob eine biologische Probe ein Polynukleotidanalyt enthält, das die Schritte umfasst:

55      Erhalten einer auf die Anwesenheit des Polynukleotidanalyten zu testenden biologischen Probe; Kombinieren der biologischen Probe mit einem Pseudoziel, um zu einer gemischten Probe zu führen; Isolieren der Nukleinsäuren der gemischten Probe, wobei **dadurch** eine Sammlung von Molekülen erhalten wird, die das Pseudoziel und jedes von den Polynukleotidanalyten, die in der biologischen Probe enthalten sind, umfasst;

60      Durchführen einer Polynukleotidamplifizierungsreaktion, um das Pseudoziel und jedes von den Polynukleotidanalyten, das in der Sammlung von Molekülen enthalten ist, zu Co-amplifizieren, um Amplifikationsprodukte zu erhalten, wobei Pseudoziel-Amplikons gebildet werden und wobei Analyt-Amplikons gebildet werden, wenn die Sammlung von Molekülen die Polynukleotidanalyte einschließt;

65      Detektion von jedem von den Analyt-Amplikons in den Amplifizierungsprodukten, ohne die den Pseudoziel-Amplikons zu detektieren; und Bestimmung, dass die biologische Probe das Polynukleotidanalyt enthält, wenn die Analyt-Amplikons in den Amplifikationsprodukten detektiert werden.

70      32. Das Verfahren gemäß Anspruch 31, wobei die Amplifizierungsreaktion aus der Gruppe, die aus einer transkriptionsvermittelten Amplifizierungsreaktion, einer NASBA-Reaktion und einer PCR-Reaktion besteht, ausgewählt wird.

75      33. Das Verfahren gemäß Anspruch 32, wobei die Amplifizierungsreaktion eine transkriptionsvermittelte Amplifizierungsreaktion ist.

80      34. Das Verfahren gemäß entweder Anspruch 32 oder Anspruch 33, wobei der Detektionsschritt zuerst das Hybridisieren einer markierten Polynukleotidprobe, die Bindungsspezifität für Analyt-Amplikons besitzt, und dann das Messen des Ausmaßes der spezifischen Bindung der markierten Polynukleotidprobe und der Analyt-Amplikons

umfasst.

35. Das Verfahren gemäß Anspruch 34, wobei der Isolierungsschritt das Immobilisieren von dem Pseudoziel und dem Polynukleotidanalyten an einen festen Träger umfasst.

5 36. Das Verfahren gemäß Anspruch 34, wobei der Detektionsschritt das Detektieren über Luminometrie umfasst.

37. Das Verfahren gemäß Anspruch 36, wobei das Polynukleotidanalyt aus HIV-Virionen stammt.

10 38. Das Verfahren gemäß Anspruch 37, wobei das Pseudoziel eine Sequenz besitzt, die aus der Gruppe, die aus SEQ ID NO:4 und SEQ ID NO:9 besteht, ausgewählt wird.

### Revendications

15 1. Procédé de quantification de polynucléotides d'un analyte présents dans un échantillon à tester, comprenant les étapes consistant à :

20 combiner une quantité prédéterminée d'un échantillon à tester avec une quantité prédéterminée d'une pseudo cible, ledit échantillon à tester contenant une quantité inconnue de polynucléotides d'analyte ;

25 co-amplifier dans une réaction d'amplification des polynucléotides la pseudo cible et l'un quelconque des polynucléotides de l'analyte contenus dans ledit échantillon à tester pour produire une collection de produits d'amplification, ladite collection comprenant à la fois un amplicon d'analyte si ledit échantillon à tester contenait les polynucléotides d'un analyte et un amplicon de pseudo cible ; et

30 quantifier l'amplicon d'analyte sans se référer à la quantité d'amplicon de la pseudo cible, de sorte que la quantité d'amplicon d'analyte soit reliée d'une manière qui dépend de la dose à la quantité inconnue des polynucléotides d'analyte contenus dans ledit échantillon à tester.

35 2. Procédé selon la revendication 1, dans lequel l'étape de quantification comprend l'hybridation de ladite collection de produits d'amplification provenant de l'étape de co-amplification avec une sonde marquée spécifique de l'amplicon d'analyte mais pas de l'amplicon de pseudo cible puis la détection de toute sonde marquée qui s'est hybridée de manière spécifique à l'amplicon d'analyte.

40 3. Procédé selon la revendication 2, dans lequel ladite réaction d'amplification des polynucléotides dans l'étape de coamplification est choisie parmi le groupe constitué d'une réaction d'amplification médiée par une transcription, d'une réaction NASBA et d'une réaction en chaîne par polymérase.

45 4. Procédé selon la revendication 3, dans lequel ladite réaction d'amplification des polynucléotides est la réaction d'amplification médiée par une transcription.

50 5. Procédé selon soit la revendication 3 soit la revendication 4, comprenant en outre une étape consistant à libérer des acides nucléiques contenus dans ledit échantillon à tester, ladite étape de libération étant effectuée de manière préliminaire à ladite étape de combinaison.

55 6. Procédé selon la revendication 5, comprenant en outre une étape de capture desdits polynucléotides d'analyte sur un support solide avant ladite étape de co-amplification.

7. Procédé selon la revendication 6, dans lequel le support solide est une bille dérivée avec un polynucléotide synthétique.

8. Procédé selon la revendication 6, dans lequel la quantité prédéterminée de ladite pseudo cible dans l'étape de combinaison est comprise entre  $1,0 \times 10^3$  et  $2 \times 10^8$  molécules, de préférence entre  $1,0 \times 10^4$  et  $2 \times 10^8$  molécules, et de manière davantage préférée entre  $1,0 \times 10^5$  et  $2 \times 10^8$  molécules.

55 9. Procédé selon la revendication 5, dans lequel le spécimen biologique est un échantillon sanguin ou un échantillon plasmatique et dans lequel lesdits acides nucléiques comprennent des acides nucléiques viraux.

10. Procédé selon la revendication 9, dans lequel le polynucléotide d'analyte est libéré à partir de virions VIH.

11. Procédé selon la revendication 5, dans lequel la quantité pré-déterminée de la pseudo cible dans l'étape de combinaison est comprise entre  $1,0 \times 10^3$  et  $2 \times 10^8$  molécules, de préférence entre  $1,0 \times 10^4$  et  $2 \times 10^8$  molécules, et de manière davantage préférée entre  $1,0 \times 10^5$  et  $2 \times 10^8$  molécules.

5 12. Procédé selon la revendication 4, comprenant en outre une étape consistant à isoler ledit polynucléotide d'analyte et ladite pseudo cible après l'étape de combinaison et avant l'étape de co-amplification.

10 13. Procédé selon la revendication 4, dans lequel la quantité pré-déterminée de la pseudo cible et comprise entre  $1,0 \times 10^3$  et  $2 \times 10^8$  molécules, de préférence entre  $1,0 \times 10^4$  et  $2 \times 10^8$  molécules, et de manière davantage préférée entre  $1,0 \times 10^5$  et  $2 \times 10^8$  molécules.

14. Procédé selon la revendication 2, dans lequel ladite sonde marquée est marquée avec un ester d'acridinium.

15 15. Procédé selon la revendication 14, dans lequel l'étape de quantification comprend la mesure par luminométrie de la sonde marquée avec un ester d'acridinium hybridé de manière spécifique avec l'amplicon d'analyte.

20 16. Procédé selon la revendication 1, comprenant en outre une étape consistant à consulter une courbe standard qui concerne des quantités pré-amplification de polynucléotides d'analyte et des quantités post-amplification d'amplicon d'analyte.

25 17. Procédé selon la revendication 4, comprenant en outre une étape consistant à consulter une courbe standard qui concerne des quantités pré-amplification de polynucléotides d'analyte et des quantités post-amplification d'amplicon d'analyte.

30 18. Procédé selon la revendication 15, comprenant en outre une étape consistant à consulter une courbe standard qui concerne des quantités pré-amplification d'un polynucléotide d'analyte et des quantités post-amplification d'un amplicon d'analyte.

19. Procédé selon la revendication 4, dans lequel la réaction d'amplification médiée par une transcription emploie une 30 série appariée d'amorces oligonucléotidiques qui ont les séquences de SEQ ID NO:1 et SEQ ID NO:2.

20. Procédé selon la revendication 19, dans lequel la pseudo cible a une séquence polynucléotidique choisie parmi le groupe constitué de SEQ ID NO:4 et SEQ ID NO:9.

35 21. Procédé pour mettre en relation des quantités pré-amplification de polynucléotides d'analyte et des quantités post-amplification d'un amplicon d'analyte, ledit procédé comprenant les étapes consistant à :

obtenir une pluralité d'échantillons témoins, dans laquelle chacun des échantillons témoin a une quantité pré-déterminée différente d'un polynucléotide d'analyte ;

40 combiner chaque échantillon de ladite pluralité des échantillons témoins avec une quantité pré-déterminée constante d'une pseudo cible pour obtenir une pluralité d'échantillons témoins mélangés ;

co-amplifier dans une pluralité de réactions d'amplification à la fois la pseudo cible et le polynucléotide d'analyte présents dans chaque échantillon de ladite pluralité des échantillons témoins mélangés pour produire une collection de produits d'amplification qui comprennent un amplicon de pseudo cible et un amplicon d'analyte ;

45 quantifier l'amplicon d'analyte pour chaque réaction de ladite pluralité des réactions d'amplification sans se référer à la quantité d'amplicon de pseudo cible présent dans ladite collection de produits d'amplification ; et préparer une courbe standard ayant les quantités pré-déterminées différentes dudit polynucléotide d'analyte rapportées contre les quantités quantifiées dudit amplicon d'analyte produites dans chaque réaction de ladite pluralité des réactions d'amplification, mettant ainsi en relation les quantités pré-amplification dudit polynucléotide d'analyte dans ladite pluralité d'échantillons témoins et les quantités post-amplification d'un amplicon d'analyte synthétisé dans la pluralité des réactions d'amplification.

50 22. Procédé selon la revendication 1 ou la revendication 21, comprenant en outre une étape consistant à détecter l'amplicon de pseudo cible.

55 23. Procédé selon la revendication 6 ou la revendication 21, dans lequel ledit polynucléotide d'analyte est un polynucléotide viral.

24. Procédé selon la revendication 23, dans lequel le polynucléotide viral est un polynucléotide de VIH.

25. Procédé selon la revendication 21, dans lequel ladite quantité prédéterminée constante de ladite pseudo cible est comprise entre  $1,0 \times 10^3$  et  $2 \times 10^8$  molécules, de préférence entre  $1,0 \times 10^4$  et  $2 \times 10^8$  molécules, et de manière davantage préférée entre  $1,0 \times 10^5$  et  $2 \times 10^8$  molécules.

26. Procédé selon la revendication 21, dans lequel ladite pluralité de réactions d'amplification dans l'étape de co-amplification sont choisies parmi le groupe constitué d'une pluralité de réactions d'amplification médiées par une transcription, une pluralité de réactions NASBA et une pluralité de réactions PCR.

27. Procédé selon la revendication 26, dans lequel ladite pluralité de réactions d'amplification dans l'étape de co-amplification est une pluralité de réactions d'amplification médiées par une transcription.

28. Procédé selon la revendication 26 ou 27, dans lequel l'étape de quantification comprend l'hybridation de ladite collection de produits d'amplification depuis l'étape de coamplification avec une sonde marquée spécifique de l'amplicon d'analyte mais pas l'amplicon de pseudo cible et ensuite la détection quantitative de toute sonde marquée qui s'est hybridée de manière spécifique à l'amplicon d'analyte.

29. Procédé selon la revendication 28, dans lequel la sonde marquée est marquée avec un ester d'acridinium.

30. Procédé selon la revendication 28, comprenant en outre une étape consistant à capturer ledit polynucléotide d'analyte sur un support solide avant ladite étape de co-amplification.

31. Procédé consistant à déterminer si un échantillon biologique contient un polynucléotide d'analyte, comprenant les étapes consistant à :

obtenir un échantillon biologique à tester pour détecter la présence du polynucléotide d'analyte ;  
combiner l'échantillon biologique avec une pseudo cible pour obtenir un échantillon mélangé ;  
isoler des acides nucléiques de l'échantillon mélangé, de sorte qu'on obtienne une collection de molécules comprenant la pseudo cible et l'un quelconque desdits polynucléotides d'analyte présents dans l'échantillon biologique ;  
réaliser une réaction d'amplification des polynucléotides pour coamplifier la pseudo cible et l'un quelconque desdits polynucléotides d'analyte contenus dans ladite collection de molécules pour produire des produits d'amplification, de sorte que des amplicons de pseudo cible soient formés, et de sorte que des amplicons d'analyte soient formés si ladite collection de molécules comprenait lesdits polynucléotides d'analyte ;  
détecter dans lesdits produits d'amplification l'un quelconque desdits amplicons d'analyte sans détecter lesdits amplicons de pseudo cible ; et  
déterminer que l'échantillon biologique contient ledit polynucléotide d'analyte si lesdits amplicons d'analyte sont détectés dans les produits d'amplification.

32. Procédé selon la revendication 31, dans lequel la réaction d'amplification est choisie parmi le groupe constitué d'une réaction d'amplification médiée par une transcription, une réaction NASBA et une réaction PCR.

33. Procédé selon la revendication 32, dans lequel la réaction d'amplification est une réaction d'amplification médiée par une transcription.

34. Procédé selon soit la revendication 32 soit la revendication 33, dans lequel l'étape de détection comprend tout d'abord l'hybridation d'une sonde polynucléotide marquée ayant une spécificité de liaison pour les amplicons d'analyte puis la mesure de l'étendue de la liaison spécifique de la sonde polynucléotidique marquée et des amplicons d'analyte.

35. Procédé selon la revendication 34, dans lequel l'étape d'isolation comprend l'immobilisation de ladite pseudo cible et dudit polynucléotide d'analyte à un support solide.

36. Procédé selon la revendication 34, dans lequel l'étape de détection comprend la détection par luminométrie.

37. Procédé selon la revendication 36, dans lequel le polynucléotide d'analyte provient de virions VIH.

**38.** Procédé selon la revendication 37, dans lequel la pseudo cible a une séquence choisie parmi le groupe constitué de SEQ ID NO:4 et SEQ ID NO:9.

5

10

15

20

25

30

35

40

45

50

55







Fig. 1



**Fig. 2a**



**Fig. 2b**



**Fig. 2c**




Fig. 3a




Fig. 3b




Fig. 4b




Fig. 4d




Fig. 4a




Fig. 4c






Fig. 5

**Fig. 6**



**Fig. 7**

专利名称(译)	多核苷酸扩增方法		
公开(公告)号	<a href="#">EP1238100B1</a>	公开(公告)日	2005-09-07
申请号	EP2000948890	申请日	2000-07-21
[标]申请(专利权)人(译)	简·探针公司		
申请(专利权)人(译)	GEN-Probe公司		
当前申请(专利权)人(译)	GEN-Probe公司		
[标]发明人	NUNOMURA KIYOTADA		
发明人	NUNOMURA, KIYOTADA		
IPC分类号	G01N33/53 C12N15/09 C12Q1/68 C12Q1/6851 C12Q1/6865 G01N21/78 G01N33/566 G01N33/58 C12Q1/70		
CPC分类号	C12Q1/6865 C12Q1/6851 C12Q2545/107		
代理机构(译)	庆祝活动 , JENTSCHURA & PARTNER		
优先权	60/145432 1999-07-23 US		
其他公开文献	<a href="#">EP1238100A2</a>		
外部链接	<a href="#">Espacenet</a>		

### 摘要(译)

用于改善基于酶的多核苷酸扩增反应获得的结果的方法。更具体地，本发明的方法可用于：(1)促进模板特异性产物的扩增，使得产生的扩增子的量反映分析物的预扩增量，甚至在用低水平的分析物多核苷酸引发的反应中也是如此；(2)促进生物样本处理，使得在随后的扩增反应中产生的扩增子的量基本上不依赖于从样本中分离的分析物多核苷酸的效率；(3)控制扩增反应中产生的分析物扩增子的量。

